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Abstract 
 
Molecular imaging techniques have become an essential tool for cancer diagnosis. They have 
the potential to detect cancer at early stages and thus, they can change the outcome of the 
disease and patient prognosis. Magnetic resonance imaging (MRI) has arisen as one of the 
most promising imaging methods used for the screening of soft tumor tissues such as breast 
cancer. However, the specificity of MRI remains poor leading to misdiagnosis and many false 
positive findings. Thus, a wide range of new contrast agents (CAs) are being developed in 
order to enhance image resolution and safety in cancer diagnosis. For new drugs with an 
intended clinical use, it is necessary a deep insight into the viability of the molecule prior to 
clinical trials. Some in vitro analysis and in vivo animal studies are carried out in order to 
characterize the physicochemical properties of the compound and its toxicity. Problems to find 
the right methodology to detect and assess identity of nanoparticles after being injected into 
the blood have been previously found. In this project, a combined method to extract and 
characterize dummy particles, mimicking nanoparticles to be used as CAs, was developed. 
These particles consist of a polymeric core, which contains a metal ion inside, together with a 
coating attached to the surface. A new approach for characterization was investigated by using 
three analytical techniques: gel permeation chromatography (GPC) to extract and separate the 
nanoparticles by size, enzyme-linked immunosorbent assay (ELISA) to analyze the coating 
and inductively coupled plasma optical emission spectroscopy (ICP-OES) to analyze the core 
and metal ion. Different biological matrices, mainly serum and urine, were tested to prove 
identity. Results showed an efficient extraction of the material with a high rate of recovery by 
GPC. Moreover, the accuracy and sensitivity of ELISA and ICP-OES in detecting the coating 
and composition of nanoparticles respectively was proved. More importantly, identity of the 
extracted material in the biological matrices was demonstrated. Future studies are required to 
scale up the method and further test blood samples from in vivo trials to completely implement 
the method. However, here the first steps towards the validation of the method were performed 
which can help to understand changes in nanoparticles upon exposure to biological fluids in 
the body. 
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 1. Introduction 
Cancer is one of the leading causes of disease worldwide today. According to the World 
Health Organization, 14.1 million adults were diagnosed with cancer worldwide in 2012 and 
in the same year, it was responsible for 8.2 million deaths (1) (Figure 1). This number is 
expected to increase to 24 million cases by 2035 (2).  
 
Figure 1. Estimation of cancer deaths and new cases worldwide in 2012 (Image modified from 
http://www.cancerresearchuk.org/cancer-info/cancerstats/world/cancer-worldwide-the-global-picture) (3). 
Lung cancer is the most common type of cancer, accounting for 13 % of the total number of 
new diagnosed cases in 2012 followed by female breast cancer with 1.7 million new cases in 
the same year. Colorectal and prostate cancers are the next most abundant types of cancer on 
the list with 1.4 and 1.1 million new cases respectively (3). Breast cancer is the most common 
cancer type in women worldwide and represents one in four of all cancers among females (2). 
In fact, the incidence of this cancer is increasing in developed and developing countries due to 
an increment in the life span, urbanization and changes in the diet and lifestyle. Thus, there is 
an urgent need to implement more reliable early detection methods that can reduce these 
numbers and improve the prognosis of patients. Efforts should be focused not only on new 
treatments but also on early prevention and detection.  
An accurate cancer screening requires high specificity and sensitivity. Some of the molecular 
imaging techniques available today are X-ray computed tomography (CT), optical imaging 
(OI), ultrasound (US), magnetic resonance imaging (MRI) and radionuclide imaging including 
single-photon emission computed tomography (SPECT) and positron emission tomography 
(PET) (4).  
 
Molecular imaging is an emerging and potential tool used in cancer diagnosis, treatment and 
monitoring of tumor status (5). In the case of breast cancer, one of the most common screening 
methods used is mammography that provides an early detection and allows the treatment to be 
started before the cancer has spread. Some studies has shown that screening mammography 
helps to reduce the number of deaths in women over the age of 50 but women under that age 
do not benefit from this method (6). Moreover, mammography as well as CT and radionuclide 
methods (PET and SPECT), uses ionizing radiation that has the potential to cause cancer in 
repeated exposures. Another drawback of the mammography is its low sensitivity, missing a 
considerable number of tumors that require additional testing such as biopsy or ultrasound. 
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 Thereby, these traditional screening technologies together with some of the most relevant 
treatments, such as surgery, radiation therapy and chemotherapy cause damage of healthy 
tissue and recurrence in cancer patients (7). 
 
Altogether, there is a need for more reliable, safe, non-invasive and sensitive screening 
methods for early detection of cancer.  
 
1.1 Magnetic resonance imaging 
 
MRI has arisen, above other imaging modalities, as the most promising imaging technique 
available today for the detection of soft tissue cancer, such as solid tumors. It is a non-invasive 
method with high temporal and spatial resolution and absence of ionizing radiation (8). Instead 
of hazard-related radiation, it uses radio frequency (RF) radiation together with a magnetic 
field to produce three dimensional acquisitions of images in vivo of organs and tissues in a 
very short period of time. It is based on the interaction between atomic nuclei and their 
movement in a magnetic field. The atomic structure is composed of a nucleus (protons, 
neutrons) and electrons orbiting around the nucleus. One important property of the atomic 
nuclei used in MRI is the tendency of the particles to rotate around an axis at a constant rate. 
Adequate atomic nuclei for MRI are those that have an unpaired proton or neutron. These 
charged nuclei that are spinning, induce a magnetic field and act as tiny magnets with a 
magnetic dipole (9). 
 
An MRI system relies on the signals from the hydrogen atoms (H), because they are highly 
abundant in the form of water within the body and have a large magnetic moment. The 
nucleus of an H atom contains an unpaired charged proton that in the absence of a magnetic 
field is spinning in a random orientation with zero magnetization. However, when an external 
magnetic field (Bo) is applied, the nuclear axes will align in the same direction as the Bo field 
(longitudinal direction) creating a net magnetization vector (NMV). These spins rotate around 
Bo at a specific frequency (ω) which is part of the RF range. If short RF pulses (excitation) are 
given at 90º to the NMV, the spins will absorb energy and change direction to the transversal 
plane. Once the pulse is switched off, the nucleus will return to its original spin state of lower 
energy in the longitudinal direction. The recovery step to the longitudinal plane is called spin-
lattice relaxation (T1) whereas the decline along the transverse plane is called spin-spin 
relaxation (T2) (Figure 2A). During the T1 recovery energy is released from the nuclei while in 
the T2 process the energy is exchanged between the nuclei (10). A radio wave signal is emitted 
at a certain frequency and detected by the voltage induced in a receiving coil after the end of 
the pulse. This voltage is registered on a computer that analyzes and converts it into an image. 
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Figure 2. Schematic description of how MRI works. A) Steps taking place during the MRI process with the 
excitation and relaxation events B) Contrast in tissues is created due to a different T1 and T2 relaxation times that 
produces different intensity signals (Image modified from Pautler, 2004) (10). 
 
Contrast in MRI images results from variations in water proton density and relaxation rates (T1 
and T2) in different tissue types causing a difference in signal strength based on changes in 
tissue water structure (Figure 2B). Normally, T1-related images are used to discriminate the 
anatomy of the body whereas T2-weighted images are used to detect abnormal tissues. In T1-
based images, a tissue with a short T1 will produce a higher intensity signal compared to 
tissues with longer T1, appearing as bright white and dark respectively (9). Since inherent 
tissue contrast is not always enough to provide high resolution, MRI contrast agents (CAs) are 
injected intravenously to increase image contrast by changing the T1 and/or T2 of water 
molecules altering the local magnetic field. Traditionally, the CAs used have been based on 
iron oxide particles and chelates of the gadolinium ion (Fe2O3 and Gd3+ respectively). 
 
A 
1. Protons-positively charged 
particles-spin in random 
directions in the absence of 
an external magnetic field. 
2. If a magnetic field, Bo, is 
applied, a small proportion of 
the spinning protons (which 
are like tiny magnets) tend to 
align with it. 
3. If the spins aligned with 
Bo are added together, they 
result in a net magnetization 
vector (NMV)… 
 
4.…that operates around Bo. 
6. When the RF is turned off, 
the transverse component 
(T2) decays and the 
longitudinal component (T1) 
recovers. 
Contrast arises because 
different tissues have 
different decay and recovery 
times (T2 and T1 values). 
Short T1 
Long T1 
5. Applying a radio frequency 
(RF) at 90º (“excitation”) 
causes the NMV to move from 
the longitudinal to the 
transverse plane. 
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 1.1.1 Contrast agents in MRI 
 
The main advantage of MRI is its high resolution although the main drawback is its low 
specificity giving false positive results. The innate differences in water content and in the 
water relaxation times T1 and T2 in the abnormal tissue are not usually high enough to produce 
a sensitive diagnosis. Therefore, there has been an increasing attempt to enhance image 
resolution by using CAs. CAs are chemical compounds that, after intravenous injection, 
increase the image contrast by enhancing the relaxation process (11). The design of these 
agents depends on physicochemical properties of these particles such as chemical 
composition, size and surface. Their ability to produce changes in the relaxation times depends 
on the intensity of the effect that they produce compared to the intrinsic relaxation times of the 
tissues (8). 
 
Certain CAs consist of super-paramagnetic particles, such as iron oxide particles, which 
reduce the T2-transversal relaxation, resulting in a darker image. The most common agents are 
based on iron oxide (Fe2O3) particles (12). Although super-paramagnetic iron oxide 
nanoparticles have been approved by the Food and Drug Administration (FDA) for human 
uses, these agents are not used any more due to negative contrast enhancement and their 
prolonged in vivo contrast enhancement, up to several months (13).  
 
The most widely used CAs include paramagnetic molecules that shorten T1 relaxation time 
giving a brighter image. Some of these molecules are chelates of the gadolinium ion (Gd3+) 
and the manganese ion (Mn2+). They contain a metal ion and a chelating ligand. The chelating 
ligand binds to the metal ion and forms a chelate complex that is excreted from the body 
without causing toxicity. Paramagnetic atoms such as Gd have one or more unpaired electrons 
with a high magnetic moment that will change the magnetic state in the H atoms. In almost 
half of the MRI diagnostic investigations, chelates of Gd ions such as Gd-diethylene triamine 
penta-acetic acid (DTPA) are used to create contrast by reducing the T1 relaxation time of 
protons in the surrounding water and thereby increasing the intensity in T1-weighted images. 
Gd ions bind to a chelate, such as DTPA, that decreases the toxicity of free Gd ions (14). The 
majority of these agents are low molecular weight compounds that diffuse into the 
extracellular space without any targeting effect. Gd CAs are efficient for the diagnosis of brain 
tumors by making possible to detect damage to the blood-brain barrier and for detection in breast 
cancer by measuring the increased uptake of agent by the tumor tissue (14). The latter exploits 
the fact that the tumors have an enhanced permeable vasculature from where the agent can 
leak into the extracellular space and the rate of this event depends on the properties of the 
neovasculature of the tumor. When the agent is delivered at high concentration rates in the 
blood, it creates a large magnetic field there compared to the surrounding tissues and causes a 
signal loss in T2 weighted images (15). 
 
However, the use of Gd-based CAs is known to give toxic side-effects, especially the 
occurrence of nephrogenic systemic fibrosis (NSF) in patients with renal failure. NSF is an 
acquired fibrosis disease that produces swelling of extremities and hardening of the skin and 
trunk that is gradually spread to other organs such as lung, heart, liver and muscles causing 
sclerosis (16). Gd-chelates might cause an iron-liberating effect with an increased 
concentration of this free metal ion in serum which is highly toxic, leading to metabolic 
acidosis and fibrosis (17). Moreover, patient-related factors also have an influence in the 
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 development of this disease when being exposed to Gd ions. In fact, the half-life of Gd-based 
CAs in patients with normal renal function is around 1.3 hours whereas the clearance rate is 
slower in those that have an impaired renal function with an increasing half-life and more 
probability of toxic ion release (18). 
 
Therefore, new contrast agents are needed in order to increase safety and resolution in cancer 
diagnosis. 
 
1.2 Nanoparticles for cancer diagnosis and therapy 
 
Nanotechnology in cancer has emerged as a new potential field which includes the design of 
material in a scale range from 1-100 nanometers with clinical use for cancer therapy and 
diagnosis. These nanoparticles (NPs) are versatile molecular devices with diverse applications 
in clinical medicine as drug-delivery carriers through passive or active targeting and as 
diagnostic tools. The advantage of using nanotechnology is the wide range of functionalities 
that can be introduced in the nanoparticle structure. These modifications include the addition 
of ligands to the surface, modification of the surface with coatings that increase circulation 
times and loading of a therapeutic drug among others (19). Although there is an increasing 
number and variety of nanoparticles, the majority of them can be classified into two main 
types: particles made of organic molecules as the main component and inorganic particles 
usually containing metals as a core (Figures 3A and B). 
 
 
 
Figure 3. Most important types of nanoparticles for imaging diagnosis and therapy A) Different types of organic 
and inorganic particles 1. Nanotubes, composed of rings, can carry a drug inside or attached to the sides 2. 
Dendrimers, globular macromolecules with branching ends 3. Solid lipid nanoparticle 4. Polymeric nanoparticles, 
made of cross-linked polymers 5. Nanocrystals 6. Liposomes, colloid structure with a lipid bilayer 7. Inorganic 
nanoparticle 8. Polymeric micelles with an aqueous core and polymer shell (Image modified from Athar and Jyoti 
Das, 2013) (66) B) Detailed description of a polymeric nanosphere composed of a central core and a coating 
attached to the surface (Image modified from Nazir et al., 2013) (20). 
A 
B 
Drug/ Paramagnetic ion 
 1                      2                        3                 4             5                6                       7                   8 
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 Carbon nanotubes, liposomes, dendrimers and micelles have been used for clinical 
applications since they can be conjugated with therapeutic agents and targeting ligands. 
Liposomes have been used as vectors for drug-delivery in breast cancer and dendrimers have 
the potential to visualize abnormal tissues through MRI (21). The majority of inorganic 
nanoparticles have a common structure that contains a central core which defines the 
magnetic, optical or fluorescent properties and an external coating on the surface that isolates 
and protects the core from degradation. Within this group, paramagnetic and super-
paramagnetic particles are used for MRI diagnosis. Recently, Mn-based contrast agents have 
gained attention as a potential alternative. This new approach is based on the fact, that unlike 
lanthanides such as Gd, Mn is native to the body as a cofactor for enzymes (22). 
 
In this context, the company Spago Nanomedical AB is currently involved in the development 
of an innovative nanomaterial, called IonXgel, with an intended clinical use. IonXgel is used 
together with Mn to create a nanoparticle-based contrast agent that can improve early 
diagnosis in cancer through MRI. It has been demonstrated that this nanomaterial enables a 
better detection of small tumors in soft tissues such as in breast cancer and thus, it will be able 
to decrease the number of false positives (23). The main component is a nanomaterial made of 
organosilicophosphonate polymers coated with polyethylene glycol (PEG) where either a 
paramagnetic ion such Mn or Gd can be loaded. These nanoparticles have medical 
applications as MRI contrast agents. 
These particles will accumulate selectively in the tumor tissue through passive targeting 
caused by physiological differences between the normal and the tumor tissue due to the so 
called enhanced permeability and retention (EPR) effect. 
 
1.3 Passive targeting: the enhanced permeability and retention effect 
 
The advantage of designing particles in the nanometer scale is that they can leak out to 
specific sites in the tumor thanks to an enhanced permeability in the tumor vasculature (Figure 
4). In fact, passive targeting is achieved because of the distinctive anatomical and 
physiological characteristics of the tumor microenvironment. Some of the main features in the 
development of cancer are an acidic pH, hypoxia, hypoglycemia, inflammation and genetic 
mutations (20). 
 
When cancer cells start to grow in a fast and uncontrolled manner, they begin to create new 
blood vessels to supply their oxygen and nutrition demands, during the so called angiogenesis 
(24). However, these blood vessels are defective and present fenestrations between the 
endothelial cells as well as an elevated production of vascular permeability mediators such as 
nitric oxide. They are characterized by a disorganized structure lacking a functional lymphatic 
drainage system which gives retention of the particles in the tumor tissue for a longer time. 
Consequently, the delivery of a certain size particle through passive targeting causes the 
extravasation of this particle through the abnormal blood vessels and its accumulation in the 
tumor tissue at a higher concentration than in normal tissues (Figure 4) (25). The low pH in 
tumor tissues has also been exploited to deliver drug-carriers such as micelles and drug-
conjugates that lose their structure and release the therapeutic component at an acidic pH (20). 
The heterogeneous nature of tumors makes ligand-mediated targeting difficult. However, the 
EPR effect uses the unique characteristic of leaky tumor vasculature which is common for 
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 almost all solid tumors regardless of other specific features (25). Thus, the importance of the 
EPR effects resides in the ability to target a wide variety of tumors. 
 
 
 
 
Figure 4. Nanoparticles are delivered to the tumor using a passive targeting strategy in which the molecules 
accumulate at the tumor spots leaking from the abnormal vasculature and will remain longer there. The EPR 
effect allows these events due to the differences in the design of the blood vessels between tumor and normal 
tissues: enhanced permeability, fenestrations and chaotic architecture (Image modified from Nazir et al., 2014) 
(20). 
 
 
1.4 PEGylation of nanoparticles 
The surface of nanoparticles can be coated with either biodegradable or non-biodegradable 
polymers to avoid undesired interactions once they are delivered into the blood circulation. 
PEG is the most commonly used non-ionic and hydrophilic polymer to coat the surface of 
particles intended for medical use. It consists of a combination of different numbers of 
ethylene glycol monomers that modify the interface layer between the nanoparticle core and 
the surrounding environment (26). It is inexpensive and it has been approved by the FDA for 
more than 20 years.  
PEG reduces aggregation events that otherwise can cause molecular trapping in the liver or 
lungs by capillary occlusion. It also decreases the uptake by the organs of the 
reticuloendothelial system (RES) (liver and spleen) increasing the circulation time in the blood 
of the nanoparticles, and thus, their half-life and biodistribution (27). In consonance, 
PEGylated molecules show a decreased interaction with proteins or other blood components as 
well as lower accessibility to enzyme degradation and immune recognition (Figure 5). Thanks 
to the hydrophilic properties, it provides the PEGylated molecule with high solubility that 
increases its stability in aqueous matrices such as water, serum and urine. However, some 
adverse effects arise from the metabolism of PEG caused by secondary products. Moreover, it 
is non-biodegradable and it might cause some hypersensitivity reactions (28). 
A=Drug 
B=Tight packing of normal vasculature 
preventing drug uptake by normal body 
tissue 
C=Permeation of drug to tumors through 
leaky blood vasculature (EPR effect) 
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Figure 5. PEG decreases the uptake from the RES as well as the interaction with blood proteins and molecules 
from the immune system such as opsonins. (A) When a naked particle enters the body, it is covered by opsonins 
that trigger the action of macrophages and liver uptake (B) When a particle coated with PEG enters the body, it 
remains hidden from the opsonins, increasing its bioavailability for the intended purpose (Image reproduced from 
Jokerst et al., 2011) (26). 
1.5 Protein-nanoparticle interaction: the protein corona 
Upon exposure to a biological fluid, nanoparticles interact with proteins that may adsorb to 
their surface forming the so called nanoparticle-protein corona. This protein corona can affect 
the biodistribution and cellular uptake of the nanoparticles in vivo. The process is a dynamic 
event where the interactions are constantly changing due to different affinities of the proteins 
for the nanoparticles. Long-lasting binding of proteins will form a “hard” corona whereas a 
more rapid and weak adsorption will create a “soft” corona (29). The composition of this 
corona is variable and depends on the amount of available proteins, the surface properties of 
nanoparticles and the surrounding environment. In human plasma, the highest abundant 
proteins such as serum albumin, immunoglobulins and apolipoproteins might be the first ones 
binding to the surface of nanoparticles. Other proteins, such as opsonins, can also coat the 
nanoparticles creating a hallmark that is recognized by the immune system leading to a 
phagocytosis event that increases liver uptake. The result is a decreased circulation time and 
an increased clearance rate (30). Moreover, binding of proteins affects the size of particles. 
Smaller particles possess higher surface to volume ratios which causes more proteins will bind 
a nanoparticle (relative to its mass) than larger particles. Consequently, particles that have 
become bigger may aggregate, become trapped in some organs and have lower filtration rates 
(31). Thus, the analysis of protein binding profiles and identification of possible candidates is 
essential to determine the nanoparticle safety and efficacy. The protein corona might be 
important to understand the pharmacokinetics and pharmacodynamics of nanoparticles in the 
body. 
1.6 Characterization of nanoparticles for therapy 
An adequate characterization of nanoparticles through a number of regulatory studies should 
be done before nanoparticles intended for clinical use can enter clinical trials. During the 
preclinical development, in vitro tests and in vivo animal studies are performed to analyze the 
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 physicochemical properties, toxicity profile and pharmacokinetics (absorption, distribution, 
metabolism and excretion) of the particles of interest (Figure 6) (32). The first step in the 
preclinical characterization of nanoparticles is to evaluate the properties of the material 
through a physicochemical characterization. This study includes analysis of particle size, 
chemical composition, surface charge, shape, purity, stability and solubility (32). The 
assessment of these properties should be the proof that the particles retain their initial identity 
after being injected into the blood. A wide range of analytical methods are available today to 
extract, separate and detect nanoparticles in biological samples. These techniques allow 
examining the properties of nanoparticles and their fate in the body (33). For example, when 
analyzing particles in a complex matrix, a separation based on size is normally required. 
Different types of techniques are used for this purpose, such as liquid chromatography 
procedures, field flow fractionation (FFF) and capillary electrophoresis. However, when using 
these separation approaches the differentiation between nanoparticles and proteins of the same 
size is still a challenge (34). Moreover, a verification of the fractionation is often needed and 
thus, a further analysis of the size, using light scattering techniques such as dynamic light 
scattering (DLS) and electron microscopy (EM) techniques. The latter includes transmission 
and scanning-electron microscopy (TEM and SEM respectively). The advantage of using 
microscopy related techniques is that the shape and aggregation tendency can also be verified.  
 
Figure 6. Currently strategy for the characterization of nanoparticles. It includes A) physicochemical 
characterization  B) in vitro analysis of blood contact properties, cytotoxicity and safety aspects C) in vivo animal 
studies to evaluate biodistribution and toxicity (Image reproduced from 
http://nano.cancer.gov/action/news/featurestories/monthly_feature_2006_july.asp) (35). 
However, in EM images it is difficult to completely identify particles or to evaluate if a 
complex nanoparticle retains its integrity during the metabolism within the body. Thus, one of 
the first challenges when choosing a method to characterize a nanomaterial is the ability to 
detect a specific element within a complex matrix. Compared to size and aggregation events, 
the elemental composition of a nanoparticle normally does not change in the biological matrix. 
Thereby, the composition “hallmark” can be examined to identify and quantify the particles in 
biological samples, as long as they can be detected. For particles that can be observed by EM, 
X-ray microscopy-based techniques, such as energy dispersive X-ray (EDX) can be used to 
detect the location of nanoparticles in tissues (34). Other element-specific modalities such as 
9 
   
 inductively coupled plasma optical emission spectroscopy (ICP-OES) and inductively coupled 
plasma mass spectrometry (ICP-MS) offer higher sensitivity than X-ray-based techniques and 
can differentiate between distinct isotopes of the same element (36). 
An alternative approach when the instrumental analysis offers poor resolution is the use of 
biological sensors which exploits the natural occurring interactions in the living organisms. 
Some examples of biosensors are the use of specific antibodies and enzymes such as in the 
enzyme-linked immunosorbent (ELISA) assays, interactions of particles with cell surface 
proteins and reporter genes that have a selective response to certain nanoparticles and coatings 
(37). Sampling methods are also a key step to further analyze the extracted particles. It is of 
high importance to determine the minimum sample volume required to have an illustrative 
sample according to the desired study (34). 
A potential strategy to define the properties of nanoparticles is the combination of several high 
accurate techniques. In this project, a powerful combination of different methods to keep track 
of the nanomaterial identity after being exposed to biological matrices has been developed. 
This new procedure allows a rapid and inexpensive quantification of nanoparticles in a 
complex matrix, such as human serum, that can be implemented in blood and other tissues 
later on. Moreover, it offers high specificity and sensitivity in low concentration samples 
despite the presence of other molecules in the mixture.  
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 2. Objectives of the project 
The final goal to achieve in this project was to demonstrate that, when the nanoparticles are 
intravenously injected in animals during in-vivo trials, the identity of the material remains 
unaffected in the blood. Problems can arise if the content of the nanoparticles is released to the 
biological fluids or if particles aggregate and lodge somewhere in the body. 
The aim of this project was to establish a combined method to extract, characterize and 
quantify nanoparticles from relevant biological matrices (e.g urine, serum, blood) using GPC-
HPLC, ELISA and ICP-OES. A dummy particle made of an organosilicophosphonate core, 
coated with a hydrophilic, covalently attached coating and filled with gadolinium was used. 
The following issues were addressed:  
-  Prove presence of the nanomaterial in the biological matrix. 
- Quantify how much of the starting nanomaterial remains in the matrix after incubation and 
extraction (prove concentration). 
- Analyze if the nanomaterial retain its physical properties in the biological matrix (prove 
identity). 
GPC fractions of smaller particles were also studied to provide information about released 
PEG or small fragments of nanoparticles present in the matrix after extraction.  
The ability of the method to study the properties of the nanoparticles after being exposed to a 
biological matrix namely, size, composition and protein interactions was evaluated. Moreover, 
several parameters to validate the method for the intended use were investigated, specifically: 
accuracy and recovery, calibration curves, limits of optimal resolution and size stability.  
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 3. Materials and Methods 
3.1 Preparation of the nanomaterial 
3.1.1    Metal loading of empty nanoparticles 
Nanoparticles consisting of a central core of silicon (Si) and phosphorus (P) with a covalently 
attached polyethylene glicol (PEG) coating were synthesized by Spago Nanomedical AB. The 
Si and P contents were determined using ICP-OES. Concentrations of Si and P were 100.4 mM 
and 77.3 mM, respectively. The pH of the solution was 5.85. 
Gd was loaded into the nanoparticles, which contained metal chelating groups. A solution of 
100 mM Gd was prepared by dissolving Gd(III) chloride hexahydrate (Sigma-Aldrich) in 
Millipore Milli-Q (MQ) water. The Gd solution was then added in a molar ratio of 1:20 (Gd:P) 
to a nanoparticle solution of 77.3 mM P in MQ water. The solutions were mixed using a 
magnetic stirrer (FALC) at 2.5 rpm and room temperature for 1 hour. The pH was adjusted to 
7.5 with 1 M Trizma Base. After the incubation, free Gd in the solution was removed by 
washing three times with MQ water on a 10 kDa centrifugal filter (Millipore) and centrifuging 
at 3500 rpm for 10 minutes and 25 ºC. Gd that was not bound to the nanoparticles passed 
through the filter whereas the particles did not go through and were retained.  
3.2 Characterization of the nanomaterial 
3.2.1 Determination of Gd-binding stability of nanoparticles 
3.2.1.1 Theoretical background 
Two procedures were used to determine Gd stability: ethylenediaminetetraacetic acid (EDTA)-
based method and non-EDTA-based method. The former relies on a chelate effect and 
measures the affinity of the nanoparticles for Gd in comparison with EDTA which acts as a 
chelating agent that captures metal ions. Gd bound to EDTA passes through a 10 kDa spin filter 
in a centrifugation step whereas the nanoparticles are retained. The latter method does not 
contain any chelating agent. It comprises a filtration step where free Gd ions from the 
nanoparticle solution pass through a spin filter and are collected as permeate. Gd concentration 
in the permeate solution after filtration is compared to Gd concentration in the nanoparticle 
solution before filtration. 
3.2.1.2 Methodology: EDTA-stability 
Nanoparticles were diluted to a concentration of 1 mM Gd in MQ water. 150 µl of  
1 mM EDTA in 50 mM Tris-HCl (pH 7.5, adjusted with 1 M HCl) was mixed with 150 µl of 1 
mM Gd nanoparticle solution and incubated for 1 hour at room temperature. After incubation, 
100 µl of the mixed solution was transferred to an eppendorf tube (pre filtration sample) and 
the remaining 200 µl of the mixture was placed into an Amicon® Ultra 0.5 ml 10 kDa 
centrifugal filter (Millipore) and centrifuged for 10 minutes at 13400 rpm. After filtration, 100 
µl of permeate was transferred to an eppendorf tube (post filtration sample). Gd concentration 
was measured with ICP-OES in pre- and post-filtration samples.  
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 The stability was calculated according to equation (1) as a percentage of the Gd that was still 
attached to the nanoparticles after incubation with EDTA. 
 
𝐺𝐺𝐺𝐺 𝑠𝑠𝑠𝑠𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑠𝑠𝑎𝑎 (%) = 100 − �[𝐺𝐺𝐺𝐺]-𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝[𝐺𝐺𝐺𝐺]-𝑝𝑝𝑝𝑝𝑝𝑝 � × 100        𝐸𝐸𝐸𝐸 (1)              
 
3.2.1.3 Methodology: non-EDTA-stability 
Nanoparticles were diluted to a concentration of 1 mM Gd in MQ water in a final volume of 
300 µl. 100 µl of 1 mM Gd nanoparticle solution was transferred to an eppendorf tube (pre 
filtration sample) and the remaining 200 µl of the solution was placed into an Amicon® Ultra 
0.5 ml 10 kDa centrifugal filter (Millipore) and centrifuged for 10 minutes at 13400 rpm. After 
filtration, 100 µl of permeate was transferred to an eppendorf tube (post filtration sample). Gd 
concentration was measured with ICP-OES in pre- and post-filtration samples. The stability 
was calculated using equation 1 as a percentage of the Gd that was still attached to the 
nanoparticles after filtration. 
 
3.2.2 DLS size analysis 
3.2.2.1 Theoretical background 
DLS is one of the most common analytical techniques used for determination of particle size 
and size distribution in suspension. This method relies on the relationship between a particle´s 
movement in liquid and its size. It measures the intensity of light scattered at a given 
scattering angle assuming that particles move randomly. This is referred to as Brownian 
motion (38). The speed of a particle´s movement called the translational diffusion coefficient 
(D) is proportional to its hydrodynamic radius (RH). RH is defined as the size of a sphere that 
has the same D as the measured particles (33). This relationship is illustrated by the Stokes-
Einstein equation shown in equation 2 where kB  is Boltzmann´s constant, T is temperature and 
η is viscosity. 
𝐷𝐷 = 𝑘𝑘𝐵𝐵 𝑇𝑇6𝜋𝜋𝜋𝜋𝑅𝑅𝐻𝐻         𝐸𝐸𝐸𝐸 (2) 
Since the particles in suspension constantly move by Brownian motion, the intensity of light 
scattered will also fluctuate depending on the size, so that small particles will produce fast 
fluctuations and large particles will produce slow fluctuations (Figure 7). These signals are 
detected and used to calculate the diffusion coefficient from which the hydrodynamic radius 
can be determined using the Stokes-Einstein equation and knowing the temperature and 
viscosity of the solution. 
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Figure 7. Intensity rate of fluctuations of scattered light from A) large particles and B) small particles in DLS. 
The intensity of the scattered light is measured over time (Image modified from Kim et al., 2014) (39). 
 
3.2.2.2 Methodology 
To determine the size of the nanomaterial, the size distribution by volume was examined by 
DLS using Zetasizer Nano ZS (Malvern Instruments) and the Zetasizer software. The size was 
measured as the volume mean diameter, defined as the diameter of a particle whose volume is 
equal to the volume of the sample when multiplied by the total number of particles. Changes in 
size distribution of nanoparticles with regards to two factors, storage time and storage 
temperature were measured (Table 1). 
 
Table 1. DLS size measurements to study storage time and storage temperature effects. The different conditions 
used for each measurement are detailed. 
 
Factor Solution Matrix Incubation * Storage temperature 
Storage 
time 
Measurement 
days 
Time 
1 Water 2h; 37ºC Room t 16 days 0-5; 8; 16 
2 SBF 2h; 37ºC Room t 16 days 0-5; 8; 16 
Temperature 
3 SBF 2h; 37ºC Room t 5 days 0-5 
4 SBF 2h; 37ºC 4ºC 5 days 0-5 
5 SBF 2h; 37ºC -20ºC ** 5 days 0-5 
* nanoparticles/matrix volume ratio=1. Incubation in water bath. 
** aliquots were prepared to avoid size changes if the same sample was thawed and refrozen several times 
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 DLS was also used to measure the size of the nanoparticles in the different matrices as well as 
the size of the fractionated material. 
Nanoparticle solutions diluted in SBF and urine were measured as is, whereas the 
nanomaterial solutions in water and HS were diluted with 225 µl of 50 mM (NH4)2CO3 (pH 
7.4, adjusted with formic acid). All samples were placed in cell disposable cuvettes (ZEN 
0040) with a final volume of 250 µl.  
Some considerations were taken into account prior to DLS measurements: transparency of 
each sample, solution concentration for optimal measurements and careful preparation of the 
sample to avoid dirt or dust particles. When necessary, the solutions were filtered using 25 
mm syringe filters with 0.2 µm GHP membrane (PALL, Life Science) to remove large 
particles prior to measurement. 
An established standard operation procedure (SOP) for size measurement was followed and 
the reported size of nanoparticles was chosen following a standard procedure (Appendix I).  
 
3.3 Incubation of nanoparticles with matrices 
The matrices used to mix with the nanoparticles were water, urine, SBF and HS. SBF and HS 
were used as the matrices to mimic physiological conditions in human blood plasma. The SBF 
buffer was prepared as follows (Table 2). 
Table 2.  Chemical components and amount of each compound in the SBF buffer. 
 
 
Chemical Compound Formula 
Purity or 
Concentration 
 
Lot Amount 
  
[% or M] Company [#] 
 
     
(g or ml) 
      Sodium Chloride NaCl ≥ 99.5 % Sigma Aldrich BCBF1709V 7,996 
Sodium Bicarbonate NaHCO3 
99.7 - 100.3 % 
(sic)  Sigma Aldrich 011M01472V 0,350 
Potassium Chloride KCl ≥ 99.5 % Fluka 70320  13007C01 0,224 
Potassium Phosphate K2HPO4 ≥ 98 % Sigma Aldrich BCBC3668V   0.174* 
Dibasic           
Magnesium Chloride MgCl2 > 95 %  
Aldrich 
Chemistry MKBD7838V    0.143
** 
           
Calcium Chloride 
Dihydrate CaCl2 • 2H2O 99 - 103 % (sic) Sigma Aldrich SZBA181AV      0.368
*** 
Sodium Sulphate 
Anhydrous Na2SO4 ≥ 99.0 % 
Fluka 
Analytical SZB93370 0,071 
Hydrochloric Acid HCl 1.0 M Solution prepared    40 ml 
Trizma Base (= "Tris") NH2(CH2OH)3 minimum 99.9 % 
Sigma Life 
Science 128K5433 6,057 
MQ water H20 100% Millipore -      1000 
  * instead of 0.228 g of K2HPO4 • H2O 
** instead of 0.305 g of MgCl2 • 6 H2O 
*** instead of 0.278 g of CaCl2 
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 One liter was prepared in a 1000 ml volumetric flask where all the reagents were dissolved in 
MQ water. The solution was mixed at room temperature using a magnetic stirrer. If the 
solution was not completely clear, it was sonicated with an ultrasonic cleaner (Branson 1510) 
for 5 minutes. The pH was then adjusted to 7.4 by adding 370 µl of 1 M HCl. 
 
HS was purchased from Sigma Aldrich (H6914) from male AB clotted whole blood and stored 
at -20 ºC. After thawing it at room temperature, the serum was centrifuged for 2 minutes at 
13400 rpm before use to avoid aggregation (40). Then, it was used as is or diluted 1:10 and 
1:100 in distilled water due to the high concentration of proteins. All these matrices were 
incubated with the nanoparticles. 
 
Urine was freshly donated by me and stored in the fridge at 4 ºC to avoid bacterial growth. It 
was filtered through a 25 mm syringe filter with 0.2 µm GHP membrane (PALL, Life Science) 
before incubation with the nanoparticles. 
 
Three nanoparticle batches were used to incubate with the matrices. They were called GF0103 
0.1R, GF01058 0.1R and GF01102 0.1R respectively when they were loaded with Gd. The 
starting concentration of each element was 77.3 mM, 100.4 mM and 3.7 mM of P, Si and Gd 
respectively. Nanoparticles were mixed at a volume ratio 1:1 with each of the five biological 
matrices. The solutions were incubated in a water bath with constant shaking for 2 hours at   
37 ºC, the physiological body temperature. After that, solutions were concentrated with 10 
kDa filters (Millipore) by centrifugation at 3500 rpm for 10 minutes and 25 ºC.  
 
3.4 Preparative GPC of nanoparticles 
3.4.1 Theoretical background 
Gel Permeation Chromatography, a type of size exclusion chromatography (SEC), separates 
molecules by size. 
GPC/SEC contains a static liquid in the pores of beads as the stationary phase and a running 
liquid acting as the mobile phase. The particles are differently retained in the pores of the 
polymer beads depending on their size. Large particles are eluted first, because they do not 
enter the beads at all, whereas small particles can enter pores in the beads, having a more 
tortuous path, so they will come out later in time (67). The equipment contains a pump to 
introduce the solvent, an injection needle, a column that holds the stationary phase, a detector 
for nanoparticles called evaporating light scattering detector (ELSD) and a software to control 
all the outputs (Figure 8).  
Figure 8. Main components of GPC/SEC equipment: pump, injector, column, detector and software (Image 
reproduced from http://polymer.ustc.edu.cn/xwxx_20/xw/201109/P020110906263097048536.pdf)  (41). 
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 The goal, when using preparative GPC, is the isolation of particles in discrete fractions. A 
fraction collector is added to the components of the GPC/SEC equipment described in figure 8 
(Figure 9A). The sample goes from the pump to the column and from the column the flow is 
split in two: 10% of the flow goes to the ELSD and 90% of the flow goes to the fraction 
collector, where it is divided for waste and collection. The tap, shown in figure 9B, regulates the 
flow direction and pressure changes occur when opening and closing this tap. Thus, it remained 
in a fixed position, as indicated in figure 9B. All the flow was coming down for collection and 
nothing was coming out for waste when the tap was in this position. 
 
 
 
 
 
 
 
 
 
 
Figure 9. GPC/SEC equipment in the preparative mode A) Overview of the equipment arrangement 1. Injector 2. 
Cable connecting the pump with the column 3. Column with the stationary phase inside 4. Fraction collector 5. 
ELSD where nanoparticles are detected B) Detailed figure of the fraction collector. 10% is going to the ELSD 
that will give a peak signal on the monitor and 90% is going to the fraction collector. The tap (T) regulates the 
direction of the flow that can be separated for waste (W) and collection (C). 
 
3.4.2 Methodology 
A YL9100 HPLC System (Dalco Chromtech) was used to collect the fractions from 
nanoparticles in water and nanoparticles mixed with SBF, HS and urine respectively. HPLC 
consisted of several parts: YL9101 (Vacuum Degasser), YL9110 (Quaternary Pump), YL9130 
(Column Compartment) and ELSD 2000 (Alltech). The Clarity HPCL software was used to 
monitor ELSD signals from the nanoparticles.  
 
A prepacked Tricorn column SuperoseTM 12 10/300 (GE Healthcare) was used with freshly 
prepared 50 mM (NH4)2CO3 buffer (pH 7.4, adjusted with formic acid) as mobile phase. The 
pH of the buffer was adjusted everyday before use. 
 
A B 
2 
5 
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 First, a baseline for pressure and ELSD signals was established by purging with 100% of 50 
mM (NH4)2CO3 (pH 7.4, adjusted with formic acid) at a flow rate of 1 ml/min. This flow rate 
was running for approximately 30 minutes until both signals, pressure (± 0.1 MPa) and ELSD 
(± 0.2 mV), were stable. Nanoparticles suspended in a biological matrix were injected onto the 
column. The injection volume was 125 µl and the flow rate was 1 ml/min. The running time 
for each injection was 30 minutes. ELSD registered 10% of the signal on the monitor as 
different peaks representing the elution times. 90% of the flow was collected in 7 separate 
fractions during the running time for a total of 5-7 injections.  
 
3.4.2.1 Determination of the delay between the fraction collector and the 
ELSD  
 
The delay between the sample exiting to the collection tube and the sample giving an ELSD 
signal on the monitor was measured. This delay was taken into account when calculating the 
collection times for each fraction. A dye, Blue Dextran (Sigma, Life Science) stored at 4 ºC in 
the fridge, was used. It was diluted to 0.01 g/ml with distilled water and then filtered using a 
25 mm syringe filter with 0.2 µm GHP membrane (PALL, Life Science). 50 µl of this solution 
was injected onto the GPC column in the preparative mode and fractions were collected each 
15 seconds between 5.45 and 8 minutes. The absorbance of each collected sample was 
measured at 220 nm in a spectrophotometer (UV-1800 CE 230V, Shimadzu) to calculate the 
time point at which the absorbance was increasing. The sample was coming to the fraction 
collector 18 seconds before the ELSD signal (0.3 minutes in the decimal system that the 
software was using). 
3.4.2.2 Fractionation of nanoparticles 
 
Time-based and peak-detection fractionation methods were used to fractionate. 125 µl of the 
nanoparticle solution was injected onto the GPC column and collection times were decided 
upon the peak separation patterns observed. Special attention was paid to the peaks given by 
the nanoparticles, which were in the range between 10-17 minutes (see 4.2.1 of Results). Once 
these times were determined, column overloading strategy was followed to fractionate. 125 µl 
of the nanoparticle solution was injected onto the GPC column for 30 minutes at a flow rate of 
1 ml/min. In total, 5-7 fractionation runs were performed for each matrix. The volume of each 
fraction correlated to the collection times. Peak separation patterns were changing due to 
fluctuations in pressure and matrix effects, so collection times were adjusted for each matrix 
(Table 3). HS as a blank matrix was also fractionated to further analyze protein-nanoparticle 
interactions. The fractionation was performed in the following order: water (1º), SBF, HS, 
urine, HS 1:10, HS 1:100 and water 2º (Appendix IX). 
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 Table 3. Collection times and volumes of each fraction in the different matrices. Retention time from the 
software and the timer times in minutes are indicated.  
Matrix Fraction Retention time (min) 
*Timer time (min) 
** 
Total 
volume 
collected 
(ml) 
Water 1º /2º) 
(Injection 
volume= 500 µl) 
# F1 5-10.5//5-10 3.42-9.12//3.42-8.42 22.0//20 
# F2 10.5-13.5//10-13 9.12-12.12//8.42-11.42 12.0//12.0 
# F3 13.5-15//13-14.8 12.12-13.42//11.42-13.12 6.0//7.2 
# F4 15.0-17.1//14.5-16.4 13.42-15.48//13.12-15.06 8.4//7.6 
# F5 17.1-18.7//16.4-18.1 15.48-17.24//15.06-16.48 6.5//6.8 
# F6 18.7-20.9//18.1-20.4 17.24-19.36//16.48-19.06 8.8//9.2 
# F7 20.9-25.0//20.4-25 19.36-23.42//19.06-23.42 16.5//18.4 
SBF (Injection 
volume= 500 µl) 
# F1 5.0-9.8 3.42-8.3 19.2 
# F2 9.8-12.0 8.3-10.42 8.8 
# F3 12.0-14.0 10.42-12.42 8.0 
# F4 14.0-16.8 12.42-15.30 11.2 
# F5 16.8-18.5 15.30-17.12 6.8 
# F6 18.5-21.2 17.12-19.54 10.8 
# F7 21.2-25.0 19.54-23.42 15.2 
Matrix Fraction Collection time (decimal system) 
Timer time (metric 
system) 
Total 
volume 
collected 
(ml) 
***HS//HS 1:10 
and 1:100 
(Injection volume 
= 500 µl) 
# F1 5.0-9.0// 5-10.8 3.40-7.40//3.42-9.30 16.0//23.2 
# F2 9.0-11.6//10.8-13.4 7.40-10.16//9.30-12.06 10.4//10.4 
# F3 11.6-14.0//13.4-14.5 10.16-12.40//12.06-13.12 9.6//4.4 
# F4 14.0-16.3//14.5-16.8 12.40-14.58//13.12-15.30 9.2//9.2 
# F5 16.3-18.2//16.8-18.4 14.58-16.52//15.30-17.06 7.6//6.4 
# F6 18.2-21.2//18.4-20.8 16.52-19.52//17.06-19.30 12.0//9.6 
# F7 21.2-25.0//20.8-25 19.52-23.42//19.30-25 15.2//16.8 
Urine 
(Injection 
volume= 600 µl) 
# F1 5-0-10.5 3.42-9.12 27,5 
# F2 10.5-13.3 9.12-12.0 14.0 
# F3 13.3-14.5 12-0-13.12 6.0 
# F4 14.5-16.8 13.12-15.3 11.5 
# F5 16.8-18.3 15.3-17.0 7.5 
# F6 18.3-21.8 17.0-20.3 17.5 
# F7 21.8-25.0 20.3-23.42 16.0 
 
 
 
 
  * The delay time between ELSD and collector was taken into account (18´´) 
** The timer was started at retention time 1.00 minute in the software 
***Blank HS was also fractionated for  further SDS-PAGE analysis 
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 3.5 Analytical GPC of nanoparticles 
3.5.1 Theoretical background 
Analytical GPC is based on the same principles as explained for the preparative mode but it 
aims to quantify and identify different compounds based on their size. It relates elution times 
and sizes of particles compared to some standard references with known sizes (63). In the 
analytical GPC, a PDA Detector UV lamp is connected to detect proteins. These proteins are 
used as internal standards to measure the retention time of the samples. The sample goes from 
the pump to the column. From the column, it goes first to the UV lamp and from there to the 
ELSD without being collected. Since the sample amount applied is lower compared to the 
preparative GPC, the peaks maintain narrow and sharp profiles in an analytical 
chromatography due to a non-saturated column (42). Because of changes in the profile peaks 
in the preparative GPC, the analytical method is preferred when analyzing the size whereas the 
preparative mode is used only for fractionation. The equipment in an analytical set-up is 
depicted in figure 10. 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. GPC/SEC equipment in the analytical mode 1. Running buffer, 50 mM (NH4)2CO3 (pH 7.4, 
adjusted with formic acid ) 2.Vacuum degasser 3. Quaternary lamp 4. PDA detector UV lamp 5. Column 
compartment 6. Injector 7. Column 8. ELSD  
3.5.2  Methodology 
The equipment in figure 10 was used to analyze both nanoparticle solutions and fractionated 
nanoparticles. First, a baseline for pressure and ELSD signals was established by purging with 
100 % of 50 mM (NH4)2CO3 (pH 7.4, adjusted with formic acid) at a flow rate of 1 ml/min. 
This flow rate was running for approximately 30 minutes until both signals, pressure (± 0.1 
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 MPa) and ELSD (± 0.2 mV), were stable. Then, the samples were injected onto the column for 
a total running time of 30 minutes and a flow rate of 1 ml/min. 
 
3.5.2.1 Size determination of nanoparticles 
Retention time for nanoparticle solutions in different matrices was determined using two 
protein references, albumin and myoglobin. For nanoparticles in human serum, protein 
standards were not added. For nanoparticles in water, SBF and urine, two protein standard 
solutions (5 mg/ml) were prepared by dissolving bovine serum albumin (BSA) (≥ 98 %  ; 
Sigma, Life Science) and myoglobin from equine heart (≥ 90 % ; Sigma Life Science) in 50 
mM (NH4)2CO3 (pH 7.4, adjusted with formic acid).  A solution of 200 µl was prepared by 
mixing 180 µl of nanoparticles with 10 µl of each protein standard solution, albumin and 
myoglobin, respectively. 50 µl of this sample was injected onto the GPC column with the 
conditions mentioned above. The delay between the UV and ELSD signals was 0.3 min in the 
software (previously determined). This delay was used to adjust ELSD peak signals and 
calculate the retention time using the albumin peak as a reference.  
 
3.5.2.2 Analysis of the fractionated nanoparticles 
The fractionated nanoparticles in the different matrices were analyzed by GPC/SEC to test if 
the fractionation was successful. 125 µl of each fraction was injected onto the GPC column 
without any protein standards. In this case, the internal reference was the corresponding 
nanoparticle solution used for fractionation. The peak separation patterns from the 
nanoparticles were compared with the peaks obtained from the fractions to check if the 
retention times were the same. 
 
3.6 Elemental analysis of components: ICP-OES 
3.6.1 Theoretical background 
ICP-OES is an analytical procedure used to quantify the concentration of a wide variety of 
materials in a sample. The equipment contains two main components: an ICP torch and the 
spectrometer detector. Argon gas is directed through the torch connected to a radio frequency 
generator. As electrical power is applied, electrical and magnetic fields are created on the top 
of the torch allowing the release of electrons from argon atoms. These electrons acquire high 
energy levels due to the magnetic field and this is known as inductive coupling. The excited 
electrons hit argon atoms and disintegrate the gas into plasma containing argon atoms, 
electrons and ions (43). The sample of interest, in liquid form, is carried through a pump into a 
nebulizer that converts the sample into aerosol drops. The analyte, in the form of an aerosol, is 
introduced into the hot plasma by a second argon gas flow. The high temperature causes the 
sample to be, first converted into solid particles and then vaporized. The resulting gas is 
atomized and ionized, releasing atoms and ions respectively (44). When these ions are excited, 
they emit light at characteristic wavelengths typical for each element. This light is detected 
and quantified through a spectrometer with a monochromator that converts the light into a 
spectrum with its constituent wavelengths (34). 
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 3.6.2 Methodology 
The concentration of Si, P and Gd in the nanoparticles and the fractionated material was 
determined by Nooshin Yousefpour and Olof Björnberg from Spago Nanomedical using ICP-
OES 710 from Agilent. Samples contained in water, SBF and urine were diluted in 1% HNO3 
whereas samples dissolved in HS were diluted in 0.1% HNO3. Standard curves of the different 
elements were made in 1% HNO3, with concentration ranges that encompassed the sample 
concentration. Limits of quantification (LOQ) for Si, P and Gd were 0.1 mg/l, 0.2 mg/l and 
0.048 mg/ml respectively. The concentrations of Si, P and Gd in the nanoparticle solution, 
obtained using ICP-OES, were used for comparison with the Si, P and Gd concentrations in 
each fraction. The amount of recovered material after fractionation was calculated. 
3.7 Anti-PEG ELISA assay 
3.7.1 Theoretical background 
Enzyme-linked immunosorbent assay (ELISA) is a biochemical test used to detect and 
quantify a molecule through antibodies, enzymes and color development. A competitive-based 
ELISA was used to quantify the concentration of PEG in the fractionated material. In this 
assay, an enzyme called PEG-Horseradish peroxidase (HRP) is mixed with the PEGylated 
samples and transferred to the wells. PEGylated molecules and PEG-HRP compete for the 
binding to anti-PEG antibodies that are attached to the bottom of the well-plate. If the sample 
contains a low PEG concentration, more PEG-HRP can bind to the antibodies whereas if PEG 
concentration in the sample is high, less PEG-HRP will bind. A substrate for the enzyme HRP, 
3, 3’, 5,5’-Tetramethylbenzidine (TMB), is added to produce color. When PEG-HRP cleaves 
the substrate, a blue color is produced. A stop solution to end this reaction is added changing 
the color from blue to yellow (Figure 11). The absorbance of the solution at 450 nm is 
inversely proportional to the amount of PEG in the samples. If the amount of PEG in the 
sample is low, more enzyme can bind to the wells, cleaving more substrate and producing an 
intense color. A higher PEG concentration in the samples will result in a weak or absent color.  
 
Figure 11. Competitive ELISA assay between PEGylated samples and PEG-HRP. PEGylated samples and 
PEG-HRP compete for the binding to anti-PEG antibodies. As a result of this competition, different 
amounts of PEG-HRP will bind to the antibodies and more or less amount of substrate will be cleaved. 
Thus, different color intensity will be obtained giving different absorbance values at 450 nm. 
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 3.7.2 Methodology 
To quantify the amount of PEG contained in each fraction, a competitive ELISA assay was 
performed using the PEG ELISA Kit RabMab ab138914 (Abcam) following the instructions 
for use provided by the manufacturer (Appendix II). The fractions were mixed with PEG-HRP 
and then placed into a microtiter plate where the anti-PEG antibodies were attached. Then, the 
mixture was incubated for 45 minutes in a shaker at room temperature and washed 3 times 
with the ELISA washing buffer provided. After that, 100 µl of a chromogenic substrate, TMB, 
was added to each well and incubated for 15 minutes protected from the light, at room 
temperature. Finally, the mixture was placed into a V-bottomed 96-well plate (Nunc TM, 
Thermo Scientific) and the optical density was measured at 450 nm using a microplate reader 
(SoftMax® Pro Microplate Reader and Analysis software). Water, SBF, HS and urine were 
used as the respective blanks for each matrix. 
A nanoparticle solution, in which the Si concentration was already determined by ICP-OES, 
was used as a reference to build a standard curve in each matrix (water, SBF, HS and urine). 
This standard solution was diluted to a concentration range between 0.2-4 µM Si. PEG 
monomer (mPEG 550, MKBR 1665V, Sigma Aldrich) was also used as another internal 
reference for PEG concentration (data not shown). Then, each fraction was diluted to 0.2-4 
µM and the absorbance values were used to calculate PEG concentration using three different 
standard equations depending on the matrix. For the first fractionation in water and for SBF 
and HS, equation 3 was used; for the second fractionation in water, equation 4 was used and 
for the urine fractionation equation 5 was used. In all these equations, x is the PEG 
concentration (µM) and y is the absorbance. 
𝑎𝑎 = 0.3473𝑒𝑒−2.336𝑥𝑥       𝐸𝐸𝐸𝐸 (3) 
𝑎𝑎 = 1.1303𝑒𝑒−3.267𝑥𝑥       𝐸𝐸𝐸𝐸 (4)  
𝑎𝑎 = 0.0918𝑥𝑥0.702           𝐸𝐸𝐸𝐸 (5) 
 
3.8 SDS-polyacrylamide gel electrophoresis 
3.8.1 Theoretical background 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) separates proteins 
only according to their size. Then, the molecular weight can be identified using standard 
proteins with known molecular weights. 
SDS is an anionic detergent that denatures the proteins by interacting with hydrophobic amino 
acids in the proteins. These amino acids are responsible for the tertiary and quaternary 
structures of the proteins. When mixed with SDS, proteins become linear polypeptide chains 
that are negatively charged and will migrate towards a positive electrode (45). 
3.8.2 Methodology 
SDS-PAGE was performed using pre-cast 12 % NuPAGE® Bis-Tris Mini Gels (Life 
Technologies). Each nanoparticle fraction (HS andHS+NPs) 1-7 was mixed in a ratio 1:4 with 
NuPAGE® LDS Sample Buffer (4x) and deionized water if needed, up to a total volume of 10 
µl. Then, the samples were heated and shaken, to further denature the proteins, using a heating 
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 block (IKA® KS 130) for 10 minutes at 80 ºC and 240 rpm. 1X NuPAGE® MES-SDS running 
buffer was prepared by adding 50 ml of 20X NuPAGE® MES-SDS running buffer to 950 ml 
of deionized water. 12 µl per sample was loaded onto a 12 % NuPAGE® Bis-Tris Mini Gel 
and 12 µl of PageRuler Prestained Protein Ladder 10-170 kDa (LifeTechnologies) was loaded 
as a protein standard to follow the molecular weight of the proteins. The gel was run for 
different times (35 min, 1h 30 min and 1h 45 min) at 200 V with 1X NuPAGE® MES-SDS as 
running buffer. 
Then, the gel was washed 3 times for 5 minutes with distilled water and stained with Simply 
Blue Safe Stain (Coomassie Blue, Life Technologies) for 1 hour with a balance shaking at low 
speed (Grant-Bio, PMR 30). Finally, it was destained overnight with distilled water and 
washed again with distilled water the next day for 1 hour. Then, it was dried and analyzed 
with the softwares GIMP 2 and Inkscape 0.91. Fractionation of HS and SDS-PAGE were 
carried out together with Evelina Folkesson at Spago Nanomedical. 
3.9    Determination of protein concentration: the Bradford assay 
3.9.1 Theoretical background 
The Bradford assay is a fast and accurate method for determination of protein concentration. It 
is based on the binding of the dye Coomassie Blue G250 to the proteins. The assay reagent 
Coomassie PlusTM contains Coomasie Blue G250 dye, methanol, phosphoric acid and distilled 
water. The free dye can exist in different ionic forms. Two of the predominant ionic forms in 
the acidic reagent are the brown and blue forms with absorbance values at 465 and 595 nm 
respectively. In the acidic conditions of the assay reagent, proteins bind to the dye and cause a 
change in the absorbance from 465 nm to 595 nm associated with a color change. Therefore, 
protein concentration is estimated by determining the amount of dye in the blue ionic form. A 
high protein concentration will give an intense blue color and a higher absorbance. Protein 
concentration in unknown samples can be calculated from a standard series of known protein 
dilutions of BSA.  
3.9.2 Methodology 
Protein concentration in four matrices (HS, HS 1:10, HS 1:100 and urine) was determined by 
the Coomassie PlusTM (Bradford) assay kit (Thermo Scientific). Standard dilution series of 
BSA were prepared in 50 mM (NH4)2CO3 (pH 7.4, adjusted with formic acid). After 
preparation of the standards, the Coomassie Plus Reagent was mixed several times by 
inverting the bottle and placed at room temperature. Then, 0.05 ml of each standard or 
unknown sample (previously diluted if needed) was mixed with 1.5 ml of the Coomassie Plus 
Reagent and incubated for 10 minutes at room temperature.  
The spectrophotometer (UV-1800 CE 230V, Shimadzu) was used to measure the absorbance 
at 595 nm. First, it was set to zero using 1 ml of distilled water placed in a UV-cuvette. Then, 
1 ml of 50 mM (NH4)2CO3 (pH 7.4, adjusted with formic acid) was placed in a UV-cuvette 
and used as a blank. After that, 1 ml of each sample was placed in a UV-cuvette and the 
absorbance was measured. 
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 The absorbance measurement for the blank was subtracted from the measurements of all the 
samples and two standards curves with the BSA standards were created (absorbance 
measurement vs. concentration in µg/ml) (Figure 12). Equation 6 was used to calculate the 
protein concentration of the unknown samples in the concentration range of 0-800 µg/ml and 
equation 7 was used to calculate the protein concentration of the unknown samples with a 
concentration range of 900-2000 µg/ml. In both equations, x is the protein concentration 
(µg/ml) and y is the absorbance. 
 
𝑎𝑎 = 0,0011𝑥𝑥 + 0,0196       𝐸𝐸𝐸𝐸 (6) 
𝑎𝑎 = 0,3206 ln(𝑥𝑥) − 1,2882       𝐸𝐸𝐸𝐸 (7)             
 
 
Figure 12. Standard curve for BSA samples. Absorbance values at 595 nm for each BSA standard were corrected 
with the blank and plotted against its concentration in µg/ml. 
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 4. Results and Discussion 
4.1 Characterization of nanoparticles in different matrices 
The ultimate aim of the project was to establish a new approach to extract and characterize 
nanoparticles first from blood and urine samples and then possibly from liver and tumors. 
Since blood was a very complex matrix to start with, I chose SBF and HS which have 
similarities in composition with blood. I proved that the nanoparticles retained their physical 
properties in the matrices and I also quantified how much of the injected material remained 
after extraction. After separating the material using GPC, I was able to prove identity and 
concentration of the extracted nanoparticles in the matrices using ICP-OES and ELISA. To 
prove identity, I characterized the nanomaterial, before and after separation, in order to 
compare the pre-and post-fractionated particles. To prove concentration, I measured Si, Gd 
and PEG concentrations of the fractions in the different matrices. First, I studied the viability 
of IXGp-Gd nanoparticles in water by analyzing the core structure, metal ion stability, PEG 
coating and size.  
 
4.1.1 Core structure 
The main structure consists of organosilicophosphonate polymers which constitute the central 
core containing Si and P atoms. An external coating made of PEG silane is covalently attached 
to the core. The core contains chelating sites with ligand binding atoms that chelate metal ions. 
The nanoparticle precursor was loaded with Gd to mimic the current nanoparticles used today 
for MRI (Figure 13). An elemental analysis of the core was performed to characterize its 
composition. 
4.1.1.1 Elemental analysis 
ICP-OES was used to perform the elemental analysis of the core with respect to Si and P 
concentrations. The core of the nanoparticles was made of cross-linked monomers. Each 
monomer contained two atoms of P and two atoms of Si (Figure 13). However, total P 
concentration was expected to be less than total Si concentration because Si also accounted for 
the PEG coating. Thus, the ratio Si/P was expected to be higher than 1.  
In fact, P and Si concentrations were 77.3 mM and 100.4 mM respectively for nanoparticles in 
water. The ratio Si/P was 1.3. P was only measurable in water because the other matrices 
contained significant amounts of P, in concentrations of 3.2 mg/dl and 0.5 mg/dl in serum and 
urine respectively (46). ICP-OES also accounted for this P concentration and gave background 
signal when measuring P concentration in nanoparticles. Therefore, P was only measured for 
the particles in water whereas Si and Gd concentrations were measured in all matrices and 
were used to compare among these matrices. 
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Figure 13. Schematic representation of the nanoparticle  structure used in this project A) General overview of the 
different components of the nanomaterial: core with chelated metal ions (Gd) and the coating, consisting on several 
PEG chains (9-12 monomers) covalently attached to the core  B) Simplified illustration showing in detail the 
composition of both the core (Si, P and Gd) and the PEG coating (PEG silane). 
 
4.1.2 Metal ion  
 
4.1.2.1 Elemental analysis 
Gd concentration, measured with ICP-OES, was 3.7 mM and it was loaded in molar ratios of 
1:20 with respect to P. Since the ratio Si/P expected in the core of each monomer in the 
nanoparticles was 1, the expected Si/Gd ratio was, thus, 1:20. Calculated Si/Gd ratio (n=3 
samples) was between 21.5 and 23. Si/Gd ratio was accounted for all the matrices (Figure 14; 
Appendix IIIA and B).  
The measured Si/Gd ratio was higher than the expected value. This difference implied that 
there was less Gd in the core. Therefore, not all Gd was incorporated into the core since after 
the loading, the free Gd was removed. However, the Si/Gd ratio was constant for all matrices 
which meant that the amount of Gd in the core was the same for all of them.  
27 
   
  
Figure 14. Calculated Si:Gd ratio in different matrices (water, SBF, HS and urine) measured with ICP-OES. 
(n=3 samples for water and HS; error bars represent the standard error of the mean (SEM)  
 
4.1.2.2 Chelating ability of nanoparticles 
Leakage of toxic ions from metal nanoparticles has been related to significant toxicity both in 
vitro and in vivo (47). Stable particles have shown low levels of toxicity compared to the ones 
that are more soluble. Thus, a stability test of metal-containing nanoparticles is used to assess 
stability related to safety levels in nanoparticles (48).  
To analyze the affinity of the nanoparticles for Gd and the strength of the binding, two 
stability tests of Gd-containing nanoparticles were performed: in the presence of EDTA and in 
the absence of a chelating agent, respectively. The first method was based on a chelation effect 
in which EDTA acted as a chelating agent that captured Gd ions. Two different concentrations 
of EDTA, 1 and 10 mM, were used to incubate with the nanoparticles. The second test was 
performed to test if the metal ion was leaking from the nanoparticle´s core without a chelate 
effect. 
The stability of Gd was expected to be close to 100% in the absence of a chelating agent 
because the nanoparticles have chelating sites for Gd. In the presence of EDTA, nanoparticles 
and EDTA compete for chelation of Gd. Thus, Gd ions are captured by EDTA and the core 
will contain lower Gd concentration than it normally has. This chelate effect should be higher 
with increasing EDTA concentrations. 
The limitation of this technique is that it cannot be used for nanoparticles contained in 
solutions with other metal ions such as calcium or magnesium because they will compete with 
Gd for the binding to EDTA giving wrong results. Therefore, the stability was only checked 
for the nanoparticles in water with reliable results (Figure 15). As expected, the stability was 
inversely proportional to the concentration of EDTA. In the presence of EDTA 1 mM, Gd 
stability was 69.1% whereas it decreased to 38% when EDTA 10 mM was added.  
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 In the experiment free of EDTA, the stability was 97.7% indicating that almost all Gd 
remained inside of the core and that the binding to the core was strong enough to avoid release 
of toxic Gd ions. According to the results, the nanomaterial had a strong ability to chelate Gd 
and thus, it migh not have toxic effects related to the release of free metal ions. 
 
Figure 15. Gd stability in percentage for different concentrations of EDTA. The stability is inversely correlated 
to the presence of EDTA. Gd stability was 69.1 % in the presence of 1 mM EDTA and 38 % in the presence of 10 
mM EDTA. In the absence of EDTA Gd stability was 97.7 %. 
It has been demonstrated that unstable nanoparticles which are diluted in biological media 
have high levels of toxicity causing the release of harmful metal ions to the extracellular 
media (48). One study done with two different soluble nanoparticles, ZnO and TiO2 incubated 
with mammalian cells, revealed that the more toxic particles were those showing a higher 
solubility in the growth media such as ZnO compared to the ones with low solubility like TiO2 
(49). Another study with two copper oxide particles with similar size, demonstrated that those 
coated and stabilized with carbon were less toxic than the soluble ones in cell culture. In the 
last case, copper ions were released to the extracellular media giving toxic effects similar to 
the ones caused by treatment of cells with equal amounts of isolated copper ions (50). These 
studies also highlight the importance of having a coating in the particles that isolates the core 
structure. 
4.1.3 PEG coating 
PEG-silane coating with 9-12 monomers was covalently attached to the surface of 
nanoparticles by Spago Nanomedical. The addition of this coating plays an important role in 
the stabilization of the nanoparticles avoiding aggregation and interaction in biological fluids 
(26). Quantification of the amount of PEG present on the surface of nanoparticles is a key step 
in the characterization of the behavior of these particles in the body. Changes in the 
concentration of PEG such as the release of PEG from the surface of nanoparticles can lead to 
toxic effects as well as to some undesired interactions and a decrease in the circulation half-
life (27). To test this issue, I used PEG coating that was not tightly attached to the core of the  
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 particles so that it could start to fall off. The aim was to study whether I could detect the 
shedding of coating with ELISA. 
4.1.3.1 Elemental and ELISA analysis 
Si:P ratio, measured with ICP, was used to calculate PEG concentration in the nanoparticles. 
Si/P ratio in the nanoparticle was expected to be higher than 1 since Si concentration was the 
largest. In fact, the measured Si/P ratio was 1.3 (Figure 16; Appendix IIIB).  
 
Figure 16.  Calculated ratios in nanoparticles from Si, P and Gd concentrations measured with ICP-OES. Si/P 
ratio was 1.3, Si/Gd was 22.4 and P/Gd was 16.8 (n=3samples; error bars represent the SEM).  
 
PEG coating was calculated as the remaining Si concentration which was not forming part of 
the core. It was determined as mol percentage of PEG in proportion to mol percentage of the 
core following equation 8. % 𝑃𝑃𝐸𝐸𝐺𝐺 = [𝑆𝑆𝑎𝑎] − [𝑃𝑃][𝑃𝑃] 𝑥𝑥 200 %          𝐸𝐸𝐸𝐸 (8) 
The percentage of PEG for nanoparticles in all matrices was 63.8 %. This equation uses the 
concentrations measured by ICP-OES. Moreover, ELISA was used to measure PEG 
concentration using Eq (3) for water, SBF and HS (Figure 17). The percentage of PEG 
obtained from the measured values with ELISA was between 66-77 %   which correlates with 
the calculated value using Eq (8).  
After evaluating the core and coating, I performed a size characterization of the material to 
determine stability. 
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Figure 17.  Relative mol % PEG coating with respect to mol % core for different matrices measured using 
ELISA and  Eq(3) as the standard curve. 
 
4.1.4 Size analysis 
DLS was used to measure the size of the nanoparticles after metal loading and compare it with 
the sizes obtained from the incubation with different biological matrices (SBF, HS and urine) 
to assess any differences. The volume mean diameter of the particles in water was between 4.9 
(±0.4) and 5.1 (±0.4) nm, similar to the volume mean diameter in SBF about 5.2 (±0.3) nm. 
However, the size increased up to 6.2 (±0.7) when particles were placed in urine which might 
be an indication of aggregation (Appendix IIIC). When measuring the size in serum the values 
obtained were not accurate due to high polydispersity in the samples (data not shown).  
The size of nanoparticles stored in water or SBF at room temperature for 16 days was 
followed to see if the size remained constant for a long period of time and there was not any 
aggregation occurring (Figure 18A; Appendix IIID). Size stability at room temperature was 
important to measure to confirm that particles stored at room temperature for a certain period 
of time did not change their size so they could still be used for in vitro tests. Also, to discard 
that any other possible observed effect was due to size changes. As shown in figure 18A, the 
size was stable around 5 to 5.7 (±0.4) nm and did not experience notable changes.  
The storage temperature of the nanoparticles and how changes in the temperature could cause 
size alterations was also analyzed. The reason behind was to confirm that when a blood 
sample was stored in the freezer, the nanoparticles conserved their original size. If some 
changes were seen in the sample, it was not because of the size changing due to storage in the 
freezer. The size of particles stored at different temperatures: room temperature, 4 ºC and  
-20 ºC was approximately the same, between 4.8 and 5.5 (±0.3) nm so the particles were 
considerably stable when stored at different temperatures for long periods of time (Figure 
18B; Appendix IIIE). 
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Figure 18. Volume mean diameter (nm) of NPs measured with DLS A) Mean diameter of NPs incubated in SBF 
or water at 37ºC for 2 hours and then stored at room temperature for 16 days (n=8-9 measurements) C) Mean 
diameter of NPs incubated in SBF at 37ºC for 2 hours and then stored at different temperatures (n=8-9 
measurements). Error bars represent the SEM. Any statistical test was used to analyze the significance of the 
study because more measurements were needed in order to conduct such study. 
In conclusion, the nanoparticles used had a volume mean diameter of 5 nm (n=7; standard 
deviation=0.37) where 92 volume % of the population was within a size range comprised 
between 2.5 and 6.5 nm (Figure 19). 
 
 
Figure 19. Mean volume percent of  NPs in water measured with DLS. The size range for 92 volume % of the 
particles was between 2.5 and 6.5 nm. 
DLS was chosen because it provides a fast and simple way to measure the size even though it 
also has some limitations. The main disadvantage is that the method is highly sensitive to dust 
and impurities in the samples. Another limitation is that the size measured depends especially 
on salt concentration (39). Increasing size particles also increase the polydispersity, with a 
wide range of size distributions. High polydispersity does not provide accurate size for 
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 particles. When measuring nanoparticles in serum, the larger proteins were masking the signal 
of the small nanoparticles, increasing the polydispersity so that the size could not be estimated 
in a reliable way (39). Several techniques are available to measure the size of nanoparticles 
and can complement DLS measurements. One is TEM which offers high resolution of the size 
and shape and direct visualization. However, the preparation of the sample can lead to 
aggregation and there is a preference for high electron dense atoms, such as Gd, reporting an 
overall size predominated by these atoms. Other methods are the nanoparticle tracking 
analysis and analytical centrifugation that offer high resolution for size distribution but longer 
measurement times (51). 
The nanoparticle size was also determined through GPC-HPLC as retention time compared to 
two reference proteins: albumin and myoglobin and their respective elution peaks (Appendix 
IVA-G). The retention time is defined as the amount of time it takes for the sample to pass 
through the column. It is measured as the time interval between the injection of the compound 
into the column and its detection as a peak on the monitor. Since albumin and myoglobin sizes 
are known, 7 and 4 nm, respectively, the nanoparticles size can be estimated by comparing the 
retention time between the nanoparticles and the proteins. The elution peak for the 
nanoparticles in water was located between the peaks of the two proteins (Figure 20). Thus, 
the estimated size for the nanoparticles using this technique was between 4-7 nm. This result 
correlates with the size obtained using DLS.  
 
Figure 20. Chromatogram from GPC-HPLC analysis showing the UV (grey) and ELSD (blue) signals from 
proteins and NPs in water respectively. A: albumin; M: myoglobin; NPs: nanoparticles: S: salts. Nanoparticle´s 
peak was coming out 1.2 minutes after the albumin peak. 
Besides, the pH of the nanoparticle solution was considered as another factor affecting the size 
through changes in the zeta potential and surface charge. Therefore, when loading the 
nanoparticles with Gd, an acid pH of 5.2 was measured and adjusted to 7.5, the physiological 
pH. Even though the analysis of the pH was not the main objective in this project, it was 
measured when incubated with the different matrices and adjusted to 7.5 when needed. A 
tendency of a decrease in the pH when the nanoparticles were standing for a certain period of 
time at room temperature was observed and this was translated into a slightly bigger size, 
which could be explained through nanoparticle aggregation. 
When entering the body, the uptake of the nanoparticles in the cells is dependent on the size, 
shape and surface charge of particles which will determine its biodistribution, retention and 
clearance rate (51). Particle size is one of the key determinants to describe the stability and 
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 behavior of particles in a given biological matrix. A decrease in size could mean a dissociation 
of particles in solution whereas an increase might be caused by aggregation (33). A constant 
size means stability and that has to be achieved when engineering nanoparticles with medical 
purposes. Matrix effect arises from the biological solution properties that might differ among 
the biological fluids. Consequently, size can be different in water than in the rest of the 
biological matrices, such as in serum or urine, where the presence of proteins and other 
biomolecules will increase the hydrodynamic radius of the nanoparticles (51). 
After testing that the material intended to be used for the project was viable, I used three 
different techniques (GPC, ELISA and ICP-OES) to establish the bioanalytical method. 
4.2 Development and validation of the bioanalysis method 
When a new compound is being developed with an intended clinical use, different analytical 
methods, for quantitative and qualitative evaluation of the molecule, are conducted to perform 
clinical and toxicology studies. The aim of any bioanalytical method validation is to ensure 
that an established quantitative procedure to detect some analytes in a biological sample is 
reliable and sensitive (52). In this project, an optimized method to assay the behavior of 
nanoparticles in different biological matrices was developed according to FDA and ICH 
guidelines on validation of bioanalytical methods for new drugs applications and registration 
in human clinical pharmacology (52) (53). 
The main parameters for a bioanalytical method validation are accuracy, precision, selectivity, 
sensitivity, reproducibility and stability according to FDA and ICH guidelines (52) (53). Some 
of the parameters analyzed in this project for the method development and validation include: 
accuracy and recovery, selectivity, calibration curves, limits of optimal resolution and 
stability. Here, the main focus will be the determination of accuracy, recovery, calibration 
curves and limits for optimal resolution. Stability of nanoparticles was analyzed in terms of 
size in the previous section and selectivity will be introduced in the next section.  
4.2.1 GPC-HPLC method for separation of nanoparticles by size 
A preparative mode in the HPLC equipment was assembled in order to separate the starting 
batch of nanoparticles by size in discrete fractions (F) that were further analyzed. The delay 
time between the fraction collector and the ELSD was measured using the dye Blue Dextran 
(see 3.4.2.1 Materials and Methods). Blue Dextran solution was injected onto the GPC column 
to analyze its retention time in the preparative mode.  
The elution peak from Blue Dextran was detected at 7.8 min on the software which 
corresponded to 7´ 48´´ on the timer (Figure 21). The dye was reinjected onto the column and 
fractions were collected, using the timer, between 5´ 45´´ and 8´´ each 15´´. The absorbance of 
each collected sample was measured to see absorbance changes (Table 4). The higher the 
concentration of the dye in the solution, the greater the amount of light absorbed. An increase 
in the absorbance was detected at 7´ 30´´ which meant that the particles were starting to be 
eluted at that time. Thus, the sample was coming to the fraction collector 18´´ before the 
ELSD signal (0.3 minutes in the software). The software detecting the signals (Clarity 
program) was using a decimal time system. However, the timer used to collect the fractions 
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 was in minutes and seconds. The decimal time system was converted into the metric time 
applicable for the timer. 
 
Figure 21. Chromatogram from GPC-HPLC analysis showing the elution peak (ELSD signal) from Blue Dextran 
(7.8 min on the software corresponding to 7´ 48´´ on the timer). 
 
    Table 4. Absorbance values from the Blue Dextran measured at 220 nm 
Collection times timer 
(min and sec) Absorbance 220 nm 
Collection times timer 
(min and sec) Absorbance 220 nm 
5´45´´- 6´ 00´´ 0.018 7´ 00´´- 7´ 15´´ 0.018 
6´ 00´´- 6´ 15´´ 0.014 7´ 15´´- 7´ 30´´ 0.016 
6´ 15´´- 6´ 30´´ 0.008 7´ 30´´- 7´ 45´´ 0.038 
6´ 30´´- 6´ 45´´ 0.009 7´ 45´´- 8´ 00´´ 0.096 
6´ 45´´- 7´ 00´´ 0.010 8´ 00´´- 8´ 15´´ 0.101 
 
To successfully separate the nanoparticles in fractions according to size, the analytical mode 
of the GPC was first used to determine the peak separation patterns and further decide the 
collection times. First, 50 µl of the nanoparticles contained in the matrix was injected onto the 
GPC column to measure the retention time of the nanoparticles using the albumin peak as a 
reference. Then, 125 µl of the nanoparticles was reinjected onto the GPC column (see 3.4.2 
Materials and Methods). The aim was to determine the maximum amount of sample volume 
that could be injected without losing resolution and check changes in the retention time with 
increasing injection volumes. When increasing the amount of sample applied to the column, 
the peak height and peak area also increase. However, the peak width and symmetry have to 
remain unchanged. If more and more sample volume is injected, it reaches a point where the 
peak height does not increase and the peaks become broader. In that situation, resolution can 
be lost and the results are not reliable anymore. To determine the collection times, first, the 
peak symmetry when overloading the column with the maximum amount of sample volume 
that could be injected (125 µl) was compared with the peak symmetry in the analytical mode. 
The collection times were then decided according to the desired peaks to be collected. The 
ELSD signal from nanoparticles was separated in 7 fractions where fractions 1 and 7 were the 
baselines, fractions 2, 3 and 4 contained the nanomaterial, fraction 5 contained the PEG chains 
of the coating and fraction 6 represented the salts (Figure 22).  
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Figure 22. Chromatogram from GPC-HPLC analysis showing the UV (grey) and ELSD (blue) signals from 
proteins and NPs in water respectively and the time intervals during which the fractions (1-7) were collected. 
Once these times were determined, the HPLC equipment was arranged for the preparative 
mode. 125 µl of the sample was injected onto the column and the peak separation patterns 
checked again. If some changes with respect to the analytical times occurred, the times were 
adjusted according to the chromatogram in the preparative mode. Collection times were 
decided based on the decimal system in the software with the range of collection from 5-25 
minutes. Then, the delay time between collector and ELSD, (0.3 minutes on the software) was 
subtracted and the time was converted into the metric system used in the timer (see 3.4.2.2 
Materials and Methods). To correlate the software and timer times more precisely, the timer 
was started 1 minute later from the software. Thus, all collection times were recalculated one 
minute ahead to compensate for the timer delay. The collection times were first set for the 
nanoparticles in water. However, peak separation patterns were changing due to fluctuations in 
pressure and matrix effects, so collection times needed to be modified for each matrix (Table 
3). A total of 5-7 fractionation runs were performed depending on the amount of volume 
sample needed for further analysis. The volume collected of each fraction correlated with the 
time span of the fraction considering that the flow was 1 ml/ min and the sample was running 
for a total time of 30 minutes.  
Column performance analysis was assessed in terms of yield since according to the FDA 
guideline, recovery of the analyte is one of the essential parameters for method validation (52). 
The yield was calculated in percentage as the amount of material recovered from the injected 
sample as shown in equation 9 where n(Fi) was the number of moles in each collected fraction 
and ninj was the number of moles injected into the column. 
𝑌𝑌𝑎𝑎𝑒𝑒𝑎𝑎𝐺𝐺 (%) = ∑ 𝑛𝑛(𝐹𝐹𝑖𝑖)7𝑖𝑖=1
𝑛𝑛𝑖𝑖𝑖𝑖𝑖𝑖
× 100      𝐸𝐸𝐸𝐸 (9) 
 
The yield was calculated with respect to Si and Gd recovery in each matrix. The aim was to 
determine the highest performance of the column in each matrix and test if any matrix was 
causing the material be stuck in the column (Tables 5A and B). The overall performance of the 
column was considerably good since in all matrices it was working over 50 % and the 
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 recovery was between 70-100 % of the injected material. This recovery was similar for Si and 
Gd. One of the lowest yields was observed in HS which can be explained by the fact that it is a 
denser medium and contains quite a lot of proteins that might affect the flow of the sample 
through the column. It could also be because of a possible interference between the serum and 
the mobile phase causing precipitation that slow down the mobility through the column (54). 
The majority of the yield was represented by fractions 2, 3 and 4 which indicates that 
nanoparticles elute in these fractions. 
Table 5. Summary of the yields (%) obtained in each fraction and for each matrix.  A) Yield (%) for Si B) 
Yield (%) for Gd. 
 
Yield (%) Si 
Fraction Water SBF HS Urine 
F1 0.19 0.69 1.13 0.50 
F2 16.20 20.41 12.40 37.45 
F3 38.47 38.80 30.51 27.50 
F4 26.83 26.11 27.30 24.02 
F5 2.27 1.61 1.62 2.77 
F6 0.46 0.34 0.29 0.67 
F7 0.06 0.09 0.08 0.12 
Total 84.48 88.06 73.37 93.03 
 
  Yield (%) Gd 
Fraction Water SBF HS Urine 
F1 1.03 0.65 0.65 2.79 
F2 36.42 23.94 42.21 57.42 
F3 55.61 42.26 30.22 22.89 
F4 11.94 10.78 4.67 3.77 
F5 0.17 0.16 0.25 0.38 
F6 0.13 0.11 0.20 0.32 
F7 0.21 0.11 0.30 0.27 
Total 105.50 78.02 78.51 87.83 
 
One of the problems that can arise when loading the column in excess is that some material is 
getting stuck in the column. Also, when overloading the column, its efficiency might decrease 
leading to variability in the retention time, loss of reproducibility and pressure increase. To 
further test the column efficiency, washing steps with 50 mM (NH4)2CO3  (pH 7.4, adjusted 
with formic acid) were done before and after a fractionation experiment and in between one 
fractionation run and the next one. These washings were done to elute any remaining material 
stuck in the column. The washing samples were collected, stored at room temperature and 
analyzed with ICP-OES. The results confirmed that there was not carry-over of sample since 
Si and Gd concentrations were below the detection limit. The column performance assessed 
here revealed that the method was accurate and precise, two of the parameters required for 
validation of a bioanalytical method. 
A 
B 
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 After fractionation, 125 µl of each fraction was reinjected in the analytical GPC mode. These 
samples were diluted in 50 mM (NH4)2CO3 (pH 7.4, adjusted with formic acid) according to 
their volumes. Analytical GPC allowed the comparison of the elution times between the 
fractions and the nanoparticle solution used for fractionation (Figures 23A and B). When the 
elution peaks from the nanoparticle solution and the fractionated material were overlapping, a 
successful fractionation was performed. 
 
 
 
 
Figure 23. Chromatogram from GPC-HPLC analysis showing A) the ELSD signal (blue) and the UV signal 
(grey) from NPs and proteins in water respectively and the time intervals during which the fractions (1-7) were 
collected B) isolated material from 2-6 fractions (2 in pink, 3 in blue, 4 in red, 5 in black and 6 in green). A 
successful fractionation was performed since the elution time of NPs and the elution times of the fractionated 
material correlated. 
When extracting and analyzing nanoparticles from blood samples post-injection a key issue is 
the presence of proteins in high concentrations. In the fractions from the nanoparticles 
incubated with HS, the presence of proteins was masking the ELSD signal from the 
nanoparticles in the GPC-HPLC chromatograms (Figures 24 A and B). Consequently, HS was 
diluted, 10 or 100 times, in distilled water before being incubated with the nanoparticles. By 
diluting the serum, protein concentration was 10 or 100 times lower and more optimal 
fractionation was achieved (Figures 24 C and D). However, to separate the fractions and have 
a better resolution in blood samples, removal of the most abundant proteins would be required. 
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Figure 24. Chromatograms from GPC-HPLC analysis showing the UV and ELSD signals fromproteins 
and NPs fractions respectively incubated with HS A) UV signal from fractions 1-4 in HS (blue, light green, 
grey and dark green respectively) B) ELSD signal from fractions 1-4 in HS (light green, red, dark green 
and blue respectively) The ELSD signal is the same as the UV signal because the presence of proteins is 
masking the nanoparticle signal C) ELSD signal from fractions 2-6 in HS 1:10 (black, brown, red, blue 
and green respectively) D) ELSD signal from fractions 2-6 in HS 1:100 (brown, red, blue, green and grey 
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 To sum up, a preparative GPC-HPLC method with ELSD detection was developed and 
validated for the extraction of nanoparticles in different matrices, namely water, SBF, HS and 
urine. Delay time, column performance, highest injection volume for optimal detection and 
matrix-dependent limitations were studied. The results showed a delay of 18´´ between the 
ELSD and the fraction collector. Column performance was efficient and the recovery of the 
injected material was adequate for the purpose of the method according to the FDA guideline, 
which states that “recovery need not to be 100 % but should be consistent, precise and 
reproducible” (52). However, the highest injection volume that still allowed optimal column 
performance was too small for the intended experiment, since a considerable volume of each 
fraction was required for further analysis by ICP. The maximum injection volume of 125 µl 
was a limitation of the extraction method, as several fractionation runs were required to 
achieve a significant amount of material. Thus, sample volume constitutes here the main 
limitation factor. Besides, overloading of the column caused an increase in the pressure and 
therefore, some instability in the elution times, leading to variability and difficulty when 
collecting the samples at fixed times. The presence of a dense matrix with high protein 
concentration, such as serum, posed a problem masking the ELSD signal of the nanoparticles 
that avoided the analytical analysis. Some improvements would involve protein removal such 
as a protein precipitation step with, for example, 5-sulfosalicylic acid that allowed the 
purification and quantification of a drug in plasma patients (55). To further improve the 
sensitivity and selectivity of the method, plasma matrix interference with the mobile phase 
around the retention time of nanoparticles could be studied (54). A good strategy to follow 
will consider to have an adequate HPLC preparative column that could optimize the process 
and conditions. 
4.2.2 ELISA assay for PEG quantification 
ELISA assay was used after separation of the particles through GPC-HPLC to quantify the 
amount of PEG in each fraction. Si/P ratio could not be used in this case to calculate PEG 
concentration since P could not be measured in the biological matrices. A dilution series of 
nanoparticles diluted with known concentration of PEG (Si) were done. Standards curves were 
prepared in the same matrix as the samples in the analysis to verify matrix effects. 
Nanoparticles were incubated with SBF, HS and urine as described in section 3.3 of Material 
and Methods. An inverse correlation between the absorbance values and PEG concentration 
was used to build the standard curves (Figure 25). One unique standard curve was used for the 
control, SBF and HS because similar absorbance values were obtained for the same PEG 
concentration which indicated high robustness. In the case of urine, a new standard curve was 
used due to different absorbance values for the same PEG concentration used in the first 
standard curve. The reason behind this difference could be a tendency of aggregation due to a 
high concentration of salts in urine. Another reason could be that the coating of these particles 
might have partially fallen off the nanoparticles. A different absorbance for PEG monomer or 
PEG on nanoparticles hence changed absorbance signal. Therefore, a new standard curve 
using the same batch of particles in water that was incubated with urine was done to allow 
comparison. The samples used as a blank were the appropriate matrix in each case (water, 
SBF, HS and urine). 
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 From these standard curves, an evaluation of the accuracy of the ELISA assay was done 
through determination of a standard deviation between the expected PEG concentration and 
the actual measurement of PEG concentration with the ELISA (Appendix V). ELISA was 
successfully working within the range of PEG concentrations used, except for the lowest 
concentration, 0.04 µmol/l, where the higher standard deviations were found. Therefore, the 
accuracy of the method decreases as PEG concentration become lower. To determine the 
analytical range in which the ELISA was working accurately, the limits of detection and 
quantitation (LOD and LOQ respectively) were calculated using the calibration curves. 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 25. Standard curves obtained through anti-PEG ELISA assay A) Standard curve for the first batch of 
nanoparticles in water and particles incubated in SBF and HS B) Standard curve for the particles incubated in 
urine C) Standard curve for the second batch of particles in water. 
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 ELISA was a highly accurate method able to quantify low concentrations of PEG. LOD and 
LOQ were calculated according to the ICH guidelines for validation of analytical procedures 
(53). LOD is defined as “the lowest amount of analyte in a sample which can be detected but 
not necessarily quantitated” (53) whereas LOQ is defined as “the lowest amount of analyte in 
a sample which can be quantitatively determined with suitable precision and accuracy” (53).  
LOD and LOQ were calculated using low concentrations of PEGylated particles added to the 
blank matrices (water, SBF and HS) and the resulting standard curves (A and B). Urine was 
excluded from these calculations due to the different behavior that could cause deviations in 
the estimations.  
LOD was determined as the lowest PEG concentration that produced a response three times 
the standard deviation of the mean signal from the blank. The absorbance values obtained 
using the different biological matrices as a blank were similar in all cases within a range 
between 0.035 and 0.038. Thus, an average of the absorbance values obtained from the blanks 
in water, SBF and HS was done and the standard deviation was calculated. LOD value was 
0.04 µmol/l. The calculated LOD correlated with the first observation based on the 
comparison between expected and measured PEG concentration.  
LOQ was calculated as the lowest concentration of the standard curve that can be measured 
precisely. From the calibration curves, 0.1 µmol/l was estimated as the lowest concentration 
with an acceptable standard deviation. The calculated LOQ agrees with the FDA bioanalytical 
method validation guideline where it is stated that “LOQ should be at least 5 times the 
response compared to blank response” (52). 
Thus, the lowest analytical range of this assay in which the method is precise might be 
between 0.04 and 0.1 µmol/l of PEG concentration. It can be concluded that this method is 
highly accurate, precise and robust for the intended use.  
4.2.3 ICP-OES method for Si, P and Gd quantification 
ICP-OES was used to determine the Si, P and Gd concentrations in the particles incubated 
with the matrices and in the resulting fractions (P only in water). All ICP-OES measurements 
were done by Nooshin Yousefpour and Olof Björnberg from Spago Nanomedical. The most 
important parameter to consider here is the reproducibility and reliability of the measurements. 
Some deviations between the expected and measured concentrations were observed.  
Prior to the measurement, samples were diluted in HNO3, at different concentrations 
depending on the matrix. Matrix effects are extremely important to consider because they can 
affect the accuracy of trace elemental analysis (56). It is known that increasing acid 
concentrations can lead to a decrease in the signal and that low concentrations of the samples 
can cause problems in terms of quantitation and detection limits (44). According to the 
established SOP, samples were normally diluted in 1% HNO3 but 0.1% HNO3 was used for 
serum samples. Some interference effects such as interactions between the proteins and the 
acid matrix might occur when using higher acid concentrations.  
A spiking test was performed to evaluate the accuracy of the method (Appendix VI). 
Correction factors to adjust the measured values and possible matrix effects were determined. 
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 All matrices were spiked with a known concentration of nanoparticles covering the range of 
concentrations detected in the fractions. These samples were measured with ICP-OES and 
deviations between the measured and expected concentrations were studied. The analyzed 
concentration range of Si and Gd was between 23-6900 µM and 1-300 µM respectively which 
covered the concentration range measured in the fractions. Two HNO3 concentrations were 
used: 1% for water, SBF and urine samples and both, 0.1 and 1% for HS. Triplicates of 
standard nanoparticles in water with known concentrations of Si, P and Gd were used as an 
internal reference to adjust the measured values. Si and Gd measurements (and P in water) 
were performed and the ratio between the expected and the measured value was used to 
generate correction factors for each element that were applied for all ICP measurements 
(Table 6). The average of the calculated correction factors in the range of concentrations 10-
300 µM Gd for water, SBF, HS and urine was done whereas in HS in the range of 
concentrations 1-300 µM Gd and in all matrices for 1 µM Gd, different correction factors were 
used because they showed distant values from the other matrices and concentrations.  
Table 6. Mean correction factors for Si, P and Gd respectively applied for ICP measurements depending on their 
concentration, biological matrix and HNO3 concentration. 
 
The importance of this optimized method resides in the ability to detect and quantify the 
nanoparticles in blood samples in a rapid and effective way, avoiding high costs and using the 
lowest amount of sample possible. For ICP-OES method, two main limitations were found: 
LOQ and volume of the fractions needed. 
The LOQ of the method for each element according to the previously established standard 
curves were: Si 0.1 mg/l, P 0.2 mg/l and Gd 0.048 mg/l. Concentration of samples should be 
higher than LOQ for an accurate quantification. In fact, some concentrations in the fractions 
were detected but they were below the LOQ and they were not quantifiable. LOQ values 
correlated with the amount of volume needed to achieve an accurate measurement. Total 
volumes needed for Si and Gd quantification in ICP-OES were 4 and 6 ml respectively. If the 
sample was enough concentrated, it could be diluted to get to these volumes whereas if it was 
too diluted, a large volume of sample was required. Using the fractionated material from the 
nanoparticles contained in HS, a theoretical calculation for the amount of blood sample needed 
for ICP-OES was done. According to some in vivo experiments performed by Spago 
Nanomedical, a dose of 20 µmol/kg (2 mM Gd) is injected in a 30 g mouse. Plasma volume in 
the mouse is 56.1 ml/kg so the concentration of nanoparticles found in the blood after injection 
at time 0 is around 5355 µM Si and 357 µM Gd. These concentrations were used for both Si 
Biological 
matrix 
HNO3 
concentration 
Element 
concentration 
range (based on 
Gd, µM) 
Si Gd P 
All 1% 10-300 0.98 0.97 0.90 
HS 0.1% 10-300 1.09 1.36 - 
Water 1% 1 1.09 1.77 - 
SBF 1% 1 1.09 1.74 - 
HS 1% 1 0.99 1.55 - 
HS 0.1% 1 1.38 1.73 - 
Urine 1% 1 1.00 1.61 - 
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 and Gd to calculate the amount of blood sample needed to measure these elements (Tables 7A 
and B). The concentration of some fractions originated from blood nanoparticles could be 
below LQ. This limitation would need to either pool blood from several mice or inject a higher 
dose in the animals.  
 
Table 7. Expected concentrations and volumes needed for ICP-OES measurement of Si and Gd in fractions from 
a hypothetical blood sample containing 5355 µM of Si (A) and 357 µM Gd (B). 
Sample Injected [Si] µM 
Dilution 
factor 
Collected 
[Si] µM 
LOQ 
[Si] 
µM 
Concentration 
factor to reach 
LOQ 
Volume 
needed for 
ICP after 
concentration 
(ml) 
Dose 
increase 
F1 5355 10465.84 0,51 3.6 6,96 28,14 281 
F2 5355 60.22 88,92 3.6 - 0,16 2 
F3 5355 32.71 163,72 3.6 - 0,09 1 
F4 5355 73.77 72,59 3.6 - 0,20 2 
F5 5355 501.89 10,67 3.6 - 1,35 13 
F6 5355 3631.01 1,47 3.6 2,41 9,76 98 
F7 5355 64044.39 0,08 3.6 42,58 172,22 1722 
Sample Injected [Gd] µM 
Dilution 
factor 
Collected 
[Gd] µM 
LOQ 
[Gd] 
µM 
Concentration 
factor to reach 
LOQ 
Volume 
needed for 
ICP after 
concentration 
(ml) 
Dose 
increase 
F1 357 2036.34 0,18 0.3 - 10,61 106 
F2 357 45.64 7,82 0.3 - 0,24 2 
F3 357 39.04 9,14 0.3 - 0,20 2 
F4 357 410.96 0,87 0.3 - 2,14 21 
F5 357 4867.67 0,07 0.3 - 25,36 254 
F6 357 8267.35 0,04 0.3 7,18 43,07 431 
F7 357 11164.67 0,03 0.3 9,69 58,17 582 
 
 
For the quantification of the nanoparticles using ICP-OES, the most important fractions are 2, 
3 and 4. For both Si and Gd, the dose would need to be increased 2 times to be able to detect 
the particles in F2 and F3. In F4, the dose would need to be increased 2 and 20 times to detect 
Si and Gd respectively. These numbers are reasonable considering that the current dose used is 
the therapeutic dose that can be increased up to 10-100 times in toxicology studies. 
 
 
 
 
 
A 
B 
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 Some studies have overcome these problems about sample volume and interferences between 
the matrix and detection signal with a convenient sample pretreatment before ICP-OES 
measurement. A combination of magnetic solid phase extraction with ICP-OES detection was 
offering a simple method for determination of trace elements in environmental and biological 
samples (57). This approach could be useful to detect Gd amounts in the samples but not for 
PEG or Si quantification. 
4.3 Characterization of the fractionated material  
After separation of the nanoparticles contained in different matrices, the fractionated material 
was further analyzed in terms of size using DLS, composition (Si and Gd) through ICP-OES 
and presence of nanoparticle coating (PEG) through ELISA. The study was performed for all 
fractions. However, the data shown in some sections is only for F2-F5 which were the samples 
containing the nanoparticles and coating. Here, the selectivity or specificity of the method was 
evaluated. Thus, the ability of the methods used to quantify the particles in the presence of 
other components, such as endogenous matrix components, was assessed. From this analysis, 
several issues can be proved: presence (detection), concentration of the nanomaterial in the 
matrix and changes in the composition such as in the coating when compared to the 
nanoparticles in water. 
4.3.1 Size analysis 
From the recovered material in each matrix, fractions 2, 3 and 4 were the samples containing 
the nanoparticles separated by size. Thus, these samples were analyzed using DLS to 
determine the size and the correlation with the chromatograms obtained from the analytical 
GPC-HPLC (Appendix VII A-F). The fractionated material was injected onto the GPC column 
to determine the relative size of each fraction containing the nanoparticles. F2 was the first 
sample eluted and F4 the last. F1 and F7 are not shown because they were the baselines and 
they did not contain any particle. From the chromatograms, it was concluded that F2 contained 
the largest particles whereas F4 contained the smallest ones. DLS was then used to determine 
the size of the fractionated material containing the nanoparticles (F2-F4). F2 encompassed the 
largest particles bigger than 15 nm, F3 consisted of the particles between 8-10 nm and F4 
contained the smallest particles below 8 nm (Figure 26). These results were consistent for 
water, SBF and urine. F2 was the most variable among the matrices and contained larger 
particles whereas F3 and F4 showed similar sizes in the different matrices. In urine, particles 
seem to be larger in F2 compared to the other matrices which correlates with the results shown 
in Appendix IIIC. The obtained sizes for each fraction matched the elution peaks from the 
chromatograms in GPC-HPLC method which indicated that the separation of nanoparticles 
was successful.  
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4.3.2 Core analysis: Si and Gd quantification 
 
An elemental analysis using ICP-OES was performed in order to measure Si, P (when 
possible) and Gd concentrations in each fraction and for each matrix. For selectivity analysis, 
Si and Gd concentrations in the blank matrices (before incubation with nanoparticles) were 
measured to avoid interference with already existing Si and Gd in the matrices. Si and Gd 
content in the blank matrices were not significant enough to cause interference (data not 
shown). The aim was to analyze the ability of the analytical method to quantify the 
nanoparticles in the matrix and detect possible changes in Si and Gd content among the 
different fractions and compared along the matrices. These differences could indicate 
alterations in the nanoparticles identity due to matrix effects. The relative abundance of Si and 
Gd in percentage per fraction was determined. The relative amount of each element was 
calculated as the percentage of Si or Gd content in each fraction with respect to the total Si or 
Gd amount respectively. The total amount was calculated as the sum of Si or Gd 
concentrations in all fractions. (Figures 27A and B) 
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Figure 26. Volume mean diameter (nm) of F2, F3 and F4 in water, SBF, and urine measured with DLS. 
n=7 measurements. Error bars represent the standard deviation.  Data was not tested with a statistical test 
because the number of experiments was insufficient to have a reasonable n. 
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Figure 27. Gd or Si content per fraction (%) with respect to the total sum of Si or Gd content in the fractionated 
material, considered as 100% . Calculations based on concentrations measured with ICP A) %Si of total Si 
injected for F2-F5 B) % Gd of total Gd injected for F2-F5. The relative Si or Gd content was calculated with 
respect to the total sum of Si or Gd content in all fractions even though the data only shows results obtained for 
F2-F5. 
The fraction value was assessed in terms of Si and Gd concentrations. The most representative 
fraction was the sample containing the highest Si and Gd concentrations. F3 was, among all 
fractions, the most representative and valuable, accounting for almost 50% of both Si and Gd 
contents. Besides, it was the most even fraction among all matrices. F2 and F4 contained 
around 20% of Si each. However, F2 contained around 30% of Gd whereas F3 around 10%. 
F5 encompassed 3% of Si and 0.5 % of Gd.  
F2 was the most variable fraction throughout the matrices, especially in urine and HS. Both 
matrices were enclosing the highest Si and Gd contents in F2 and the lowest in F4. These 
increased concentrations might be explained through an increase in size of some nanoparticles 
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 due to possible interactions with other molecules present in the matrix or aggregation of 
particles. If that is possible, there would be larger particles in the sample and these larger 
nanoparticles would elute first from the column. In other words, the nanoparticles that were 
supposed to be collected in F4, became bigger and were collected in F2. Most probably, these 
interactions are due to the presence of proteins and other molecules like salts in serum and 
urine (58). 
Recently, it has been demonstrated that some of these interactions are caused by the 
adsorption of proteins to the surface of nanoparticles which determines biodistribution in vivo 
(30). As a result of the binding of proteins to the surface of nanoparticles, a protein corona is 
created (40).  
 
4.3.3 Coating analysis: PEG quantification 
PEG concentration was measured in each fraction using ELISA. The aim was to quantify the 
coating of the nanoparticles upon incubation with the matrix. These changes were calculated 
as percentage of PEG (Si) with respect to the amount of core in each fraction measured by 
ICP-OES (Figure 28). 
The most representative fraction for PEG coating was F5 which accounted for 70-80 % of the 
PEG coating compared to the core. However, in the case of urine F5 only represented a 15% 
having the majority of PEG in F2. Thus, F2 in urine accounted for half of the PEG coating 
content with respect to the core. These results might indicate that the identity of the particles 
in urine had changed and that probably there was an aggregation that caused a larger 
proportion of PEG to appear in F2. However, the method was sensitive enough to assess the 
identity of the particles in this matrix and showed that it had changed. The aggregation event 
was also seen in the chromatogram from the GPC (Appendix IVG). Another possible 
explanation might be translated into PEG coating falling off from the nanoparticle´s surface 
causing aggregation of loose PEG molecules. Released PEG molecules interacting with each 
other were eluted in F2 which gave the highest PEG concentration in this fraction. In HS, a 
lower amount of PEG in F5 compared to the other matrices was observed. In this case, the 
presence of proteins may have caused some interference effect. Proteins can adsorb to the 
surface of the nanoparticles but they might also interact with the PEG chains from the coating. 
Protein adsorption to the PEG chains could interfere with any specific interaction such as the 
binding of PEG to anti-PEG antibodies in the ELISA assay. This protein-PEG interaction may 
have caused a decrease in the detection of PEG by ELISA. In fact, it has been reported that 
PEG chains can bind proteins and that these attractive forces are linked to changes in the 
polymer configuration (59). 
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Figure 28. %PEG Si with respect to the core component in each fraction. Calculations based on PEG 
concentration measured with ELISA and Si concentration measured by ICP-OES. Data shown for F2-F5 in each 
matrix  
 
4.3.4 Identity of nanoparticles: summary 
Overall, it was demonstrated that the PEG, Gd and Si contents were exhibiting the same trend 
in all matrices except for the urine (for PEG and Gd) (Figures 29 A, B and C). In water, SBF 
and HS, most of the PEG coating remained attached to the nanoparticles (F2-F4) whereas 
some PEG coating was falling off and appeared in F5. In HS a higher amount of PEG in F4 
indicated that PEG might be starting to fall off from the nanoparticles. In urine it seemed that 
there was a tendency of aggregation since most of the PEG coating was in F2. Urine was the 
last matrix tested and so, the first hypothesis was that the nanoparticles were losing their 
stability with time, changing their identity. For that reason, a second batch of nanoparticles in 
water was prepared. As shown in figure 29A, the second batch of nanoparticles in water 
(shown in orange) had the majority of the coating in the same fractions where the 
nanoparticles were collected. Thus, the changes observed in urine were not due to an “aging” 
effect of the nanoparticles but an effect that the urine had on the nanoparticles. In fact, the 
method developed was able to detect these changes. Also, the DLS measurements in urine 
samples gave a similar indication (Figure 26). In SBF and HS, PEG, Gd and Si contents 
remained unaffected when compared to the nanoparticles in water. The same trend as with 
PEG was observed for Gd in urine (Figure 29B). However, when analyzing the Si content, the 
differences were not that obvious (Figure 29C). Therefore, using a powerful combination of 
ELISA and ICP-OES, identity of the nanoparticles was proved. The method was sensitive 
enough to also detect changes in the identity such as in urine. Further experiments would be 
necessary using a freshly prepared batch of nanoparticles incubated with all matrices at the 
same time. 
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Figure 29. Analysis of PEG, Gd and Si contents for NPs incubated with different matrices  
A) %PEG of total PEG content in F1-F7 for the two runs in water and for SBF, HS, HS 1:10 and HS 
1:100  B) % Gd of total Gd content in F1-F7 for two runs in water and for SBF, HS, HS 1:10 and HS 
1:100 C) % Si of total Si content in F1-F7 for two runs in water and for SBF, HS, HS 1:10 and HS 
1:100 
Specificity of the method was achieved through a combination of various analytical assays. 
Two of the methods that achieved more selectivity were ELISA and ICP-OES. ELISA was a 
highly sensitive assay for the intended use. It was able to detect the coating of the 
nanoparticles over other components in the matrix for all the media analyzed. ICP-OES was 
suitable for quantifying the elemental composition of the particles (Si, Gd). However, the 
innate presence of P in the matrices did not allow a precise measurement of P. Both 
procedures maintained their specificity in a range of low concentrations. Moreover, it was 
possible to isolate particles in three main fractions (F2. F3 and F4) using GPC-HPLC where 
the ELSD signal was detected over other components of the matrix. However, some selectivity 
problems arose in HS due to a predominant presence of proteins. This issue was partially 
solved but an optimal protocol to achieve higher discrimination would be needed. The same 
scenario was obtained using DLS, which was able to measure the required particles of small 
size but in the presence of proteins, it was mainly measuring the size of the proteins. 
Thereby, specificity was not achieved in all cases and especially in serum, where several 
improvements would be required to minimize the interference caused by endogenous 
components in this matrix. 
4.4 Nanoparticle-protein interaction: the protein corona 
Upon introduction into the body, nanoparticles are exposed to biological fluids such as 
plasma. In this environment, nanoparticles can selectively bind proteins. These interactions 
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 depend on the surface properties and size of nanoparticles but also on the type of proteins and 
physiological medium (60). 
Nanoparticle-protein interactions are dynamic and different proteins participate in the 
formation of the protein corona. The amount and type of proteins bound to the surface of 
nanoparticles is variable depending on plasma proteins concentration (29).  
Studying these interactions is crucial to determine the fate of nanoparticles in vivo. Adsorption 
of proteins to nanoparticles might impact cellular uptake, biodistribution and clearance of the 
nanomaterial leading to possible toxic effects. Quantification and identification of proteins 
attached to nanoparticles is required to understand these interactions.  
4.4.1 Protein size changes in human serum  
One-dimensional gel electrophoresis was used for protein separation after incubation of 
nanoparticles with serum at a volume ratio 1:1 and subsequent fractionation. HS without 
nanoparticles was the internal reference used to compare protein size profiles. HS was 
fractionated using GPC-HPLC as the same way as the serum containing the nanomaterial and 
with the same collection times (see 3.4.2.2 of Material and Methods). 
Fractions 1-7 from HS and HS+NPs were applied to SDS-PAGE for separation of the proteins 
according to their molecular weight. The aim was to analyze possible shifts in the bands 
indicating a delay in the migration of the proteins by particle interactions. Besides, a “jump” 
of a band from one fraction to another was studied. Although fractions 1-7 were used, only 
data for fractions 2, 3 and 4 is shown where the most notable changes were observed (Figures 
30 A and B). 
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Figure 30. SDS-PAGE of fractions 2, 3 and 4 from HS and HS+NPs A) Running time 1 hour B) Running time 1 
h 45 minutes. Noticeable changes are shown in red. S= standards; HS= human serum; NPs= nanoparticles. 
 
The nanoparticles seemed to affect the protein-band patterns in some fractions such as F2 and 
F4 (red marks in figure 30). A protein band between 70-80 kDa disappeared in F4 (HS+NPs) 
whereas an additional band around the same molecular weight appeared in F2 (HS+NPs). 
These changes were noticed only in the fractions containing the nanoparticles. The HS 
fractions did not experience any appreciable change. These effects were reproducible for at 
least three experiments. This movement of bands among fractions might be explained due to 
some interactions between proteins and nanoparticles. If a protein-nanoparticle complex is 
formed, it will be eluted in an earlier fraction due to an increase in size. Thus, the protein 
adsorbed to the surface of the nanoparticle will be collected in a different fraction compared to 
when it is separated in the reference serum (HS). Therefore, the band of that protein will 
disappear in the HS+NPs fraction that contained the protein and a new band will appear in 
another fraction according to the size of the complex. 
However, the protein band remained in the same weight range as before even though it 
appeared in another fraction. The reason why the protein remained at the same weight was that 
all proteins were denatured when treated with SDS causing all tertiary and quaternary 
structures and hence, the NP-protein interactions, to be lost. Thus, the proteins are separated 
from nanoparticles and become a linear polypeptide chain with the same molecular weight as 
before. In fact, interactions that bring together different subunits from a protein are also 
broken. This means that these results might not be a proof of nanoparticle-protein interaction 
but rather a proof of interactions between nanoparticles and single subunits of a protein.  
Native gels should be used instead to detect these interactions with complete proteins. Using 
this method, proteins maintain their tertiary and quaternary structures and each band in the gel 
B
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 represents a protein. After separation, the bands of interest can be directly submitted to trypsin 
digestion and further identification using mass spectrometry techniques such as Matrix 
Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry (MALDI-TOF-MS) 
(Figure 31). However, for an accurate quantitative analysis of the protein of interest, Western 
blot or immunoblotting methods are more suitable. 
 
Figure 31. Schematic overview of the procedure most commonly followed to isolate and identify proteins 
interacting with nanoparticles. A) NPs are incubated with serum or plasma proteins that will bind to the surface 
of NPs. B) The sample is centrifuged to remove the unbound proteins and the remaining NP-protein pellet is 
washed several times. C) Laemmli buffer containing SDS denatures the proteins and release them from the 
nanoparticles. D) Released proteins are further separated using one or two dimension electrophoresis. E) The 
bands of interest are digested with trypsine and the proteins identified using mass spectroscopy (Image 
reproduced from Saptarshi et al., 2013) (29). 
If the previous results shown in figure 31 were true, a nanoparticle-protein complex was 
formed and a shift from F4 to F2 occurred. This would result in an increasing protein and 
nanoparticle concentration in F2 which correlates with the results obtained from the ICP-OES 
analysis of the fractions in serum and urine (Figures 27A and B). Using ICP-OES, an increase 
in Si and Gd contents was observed in F2 whereas a decrease occurred in F4. Thus, a higher 
nanoparticle concentration resulted in F2. 
Using nanoparticles with different properties, such as super-paramagnetic iron oxide 
nanoparticles (SPIONs), gold particles and metal oxide particles (ZnO, TiO2 and SiO2), a more 
accurate characterization of the protein corona has been made in several studies (29) (40). 
Albumin, apolipoproteins, fibrinogen, immunoglobulins and complement proteins are the most 
common proteins found in the protein corona. Complement proteins are opsonising proteins 
that can lead to an undesired immune recognition (29). 
4.4.2 Relative distribution of proteins and nanoparticles in human serum 
A quantitative analysis of protein and nanoparticle concentrations and their relative 
distribution in serum and urine fractions was performed. Relative distribution was calculated 
as the percentage of protein concentration in each fraction with respect to the total protein 
concentration in all the fractions. The aim was to study the effect of protein concentration in 
each fraction since it has been reported that the amount of proteins available to interact with 
NPs can affect the protein corona formation and composition (31). The relative distribution of 
proteins among the different fractions in human serum and urine showed a different protein 
composition in these matrices (Figure 32).  
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 In human serum, albumin is the most abundant protein with a concentration of approximately 
40-50 mg/ml and represents around 55% of the total protein content (61). This 66 kDa protein 
is eluted in F3 and the rest of the proteins are distributed almost exclusively among F1, F2 and 
F4. Thus, human serum mostly contains proteins within a range of 80-250 kDa because they 
have a native molecular weight larger than the kidney filtration cutoff (around 45 kDa) (62). Ig 
G, Ig A, transferrin, haptoglobin and antitrypsin are the other five proteins with the highest 
concentrations. Together with albumin, these six highly abundant proteins represent over 85% 
of the human serum proteome (63). Therefore, the overwhelming presence of these proteins, 
makes difficult the separation and identification of low abundance serum proteins (64).  
However, normal total protein concentration in human urine is much lower than in human 
serum. It is not usually more than 0.1 mg/ml with an excretion rate of less than 150 mg per 
day (58). Urine contains proteins coming from blood plasma, kidneys and the urogenital tract. 
It also has components from body filtrates such as water, high salt content, electrolytes and 
nitrogenous waste elements (65). Individual samples are very heterogeneous in composition 
depending on the body flow and filtration rates. Thus, these results might be different when 
analyzing other samples. The proteins in urine were distributed more evenly among all the 
fractions containing molecules from a wide range of molecular weights. A high salt content 
together with other components such as electrolytes and nitrogenous derivatives were 
collected in the “smallest” fractions (F6 and F7) and might interfere when analyzing the 
proteome. Thus, the first step reported to prepare urine samples for protein analysis is always 
the removal of salts with gel filtration and further protein concentration by ultrafiltration (65). 
 
Figure 32. Relative abundance of proteins (%) in human serum and urine fractions. A different proteomic 
composition of both matrices is clearly seen. A more even protein distribution among all fractions is observed in 
urine whereas in serum, most of the proteins are located in F1-F4. 
To determine the ratio between proteins and nanoparticles in each fraction, nanoparticle and 
protein concentrations (in µg/ml) were measured  (Appendix VIII A-D). For the nanoparticles, 
Si composition and weight were considered to calculate the concentration in each fraction. For 
the proteins, the Bradford assay was used to measure the protein amount based on a series of 
BSA standards with known concentrations (Figure 12).  
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 When fractionating nanoparticles in serum, 125 µl of a sample containing 50 mg /ml of 
proteins was injected onto the GPC column. This protein concentration value was obtained 
with the Bradford assay in reference to BSA standards and was in agreement with the normal 
concentration range of serum albumin (35-50 mg/ml) reported in several studies (61) (62). 
Thus, 6.25 mg of protein was injected. Knowing the relative protein percentage that should go 
in each fraction (figure 32) and fraction volumes, the expected protein concentration was 
calculated (Figure 33). 
 
Figure 33. Expected protein concentration (µg/ml) in each serum and urine fraction calculated using the amount 
of protein injected, the relative protein abundance in each fraction and the fraction volumes. 
F3 contained the largest protein concentration although the protein amount in serum is almost 
twice the amount in urine. Serum albumin concentration in normal urine is 2.2-3.3 mg/l (58) 
which is more than a thousand times lower than in serum. F3 accounted for the most 
significant differences between both matrices. F1-F4 contained similar protein concentrations 
whereas F5-F7 encompassed filtration products in urine (salts, waste products) that are smaller 
than 45 kDa (kidney cutoff). 
Therefore, depending on the desired aim different strategies can be followed. To characterize 
nanoparticles alone, removal of high abundant proteins would make it easier. However, if 
nanoparticle-protein interactions want to be analyzed, all proteins should be present in the 
sample. 
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 5. Future work  
In this project, the first steps towards the development and validation of a bioanalysis method 
to extract and characterize nanoparticles from biological matrices were performed. However, 
to achieve a complete validation and implementation of this method as proof of identity of 
particles in biological samples, more work needs to be done. 
The next step would be the extraction of nanoparticles from different biological samples such 
as blood and liver. These particles are injected into the blood during in vivo experiments. 
Then, a sample is withdrawn from the animal and is used to study the properties of the 
nanoparticles post-injection with this method. The results would be compared with a 
nanoparticle solution in water that is not injected. The concentration of nanoparticles injected 
into the body is much lower than the concentrations used for this project. Moreover, the 
amount of sample extracted from the animal cannot be higher than 100 µl each time. Thereby, 
the limitations of the method could be studied in a better way in terms of sample volume 
needed and further sample concentration to better discriminate the nanoparticles out of the 
matrix components. It would also be interesting to study the recovery of nanoparticles from 
cell cultures. 
Some improvements to scale-up the fractionation method would be required. The acquisition 
of a preparative HPLC column would allow increasing the size in the analysis conditions by 
incrementing the column size, flow rate or sample load (injection volume). It would also be 
important to review the eluent (mobile phase) composition to make sure there is not 
interferences with the matrix components that could lead to precipitation or aggregation of 
particles. Since the obtained fractions are dissolved in the eluent, it is necessary to confirm 
that the components of the eluent do not pose a problem when analyzing the fractions by using 
other assays. Most probably, it would be required the development of a protocol for sample 
concentration after separation by size to be able to detect particles through ICP-OES. Another 
alternative could be to increase the dose in the in vivo animal studies. Also, removal of the 
highest abundant proteins through protein precipitation would allow a more “clean “signal 
from the GPC-HPLC. However, if the nanoparticle-protein interactions are further studied, a 
different procedure would be followed. Samples would contain all the plasma proteins and 
alternatively to denaturing gels, native gels would be run to keep the proteins in their original 
structure. Protein bands of interest would be identified through mass spectroscopy. After 
identification of proteins, Western blot could be used to further detect these proteins and 
quantify their expression. It would be interesting to study the effects of time incubation and 
protein concentration on protein binding to nanoparticles. 
To further study the presence of PEG in the isolated fractions, Western blot using an anti-PEG 
antibody could be done. The presence of PEG would appear in bands of different molecular 
weights in each fraction according to the size of nanoparticles. 
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 6. Conclusion  
This study presents a powerful bioanalytical method to extract nanoparticles from different 
matrices (water, SBF, serum and urine). Firstly, I characterized the nanomaterial in water in 
terms of chelate ability, composition and size. The results show that the size of the 
nanomaterial is 5 nm and it is composed of Si, P and Gd and 60% PEG coating. I 
demonstrated the stability of Gd inside the nanoparticles. Also, I proved long-term and short-
term size stability of these particles at different storage times and temperatures. Secondly, I 
investigated the efficiency of the methods used.  I revealed a high performance of the GPC 
column with 80% of the material recovered and high sensitivity of ELISA measuring PEG 
concentrations efficiently in a low range of concentrations up to 0.1 µ/mol. Thirdly, I 
characterized the fractionated material. F3 showed the highest Si and Gd content and was the 
fraction where the intermediate particles were collected (6-8 nm). F5 was the most 
representative fraction for PEG coating. In all matrices, most PEG coating remained attached 
to the nanoparticles in F2-F4. However, in urine it seemed that there was a tendency of 
aggregation. Nanoparticles in serum also showed some variable results. Finally, this variable 
behavior leads us to study possible nanoparticle-protein interactions in serum. Results showed 
a potential change in some protein bands but any definitive conclusion can be drawn. In fact, 
more experiments should be done to confirm these results. 
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 Appendix I 
SOP for DLS size measurements: Zetasizer Nano Malvern Instrument 
• Sample 
- Material: silica 
    Refractive index (RI): 1,450 
    Absorption: 0,001 
- Dispersant: Water 
   Temperature: 25ºC  
   Viscosity: 0,8872 centipoise (cP) 
   RI: 1,330 
   Use dispersant viscosity as sample viscosity 
- General temperature: 25 ºC 
- Equilibration time (seconds): 180 
- Cell type: Disposable cuvettes (ZEN 0040) 
- Volume: 250 µl  
     Water and HS: 25 µl + 225 µl (NH4)2CO3 (pH 7.4, adjusted with formic acid) 
     SBF and urine: 250 µl  
• Measurement 
- Angle of detection: 173º Backscatter (NIBS default) 
- Measurement duration (automatic): 
Number of runs: 11 
Run duration (seconds): 10  
- Measurements: 
Number of measurements: 10 
Delay between measurements (seconds): 0 
- Measurement settings: Automatic attenuation selection  
Allow the software to seek for the best position 
LXII 
    
 • Data processing 
- Analysis model: Multiple narrow modes (high resolution) 
 
The size of the nanoparticles was reported following the procedure below. 
- The quality of the correlogram was checked (it could not be below 0.5 and good quality 
was considered above 0.8). It should have a sigmoidal shape. 
- In the Volume PSD (M) window, the measurements deviating from the average were 
removed (by looking at the size distribution by volume graph). 
- In the Volume stats table (M) window, the size range of the nanoparticle population was 
determined including all sizes (d.nm) with a mean volume percent above 5. 
- In the records view, the volume mean (d.nm) was chosen to report the size by selecting 
the mean and standard deviation of 5-10 measurement values of volume mean. 
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 Appendix II 
ELISA assay protocol (Abcam) 
 Bring the necessary amount of well strips to room temperature. Keep the rest of reagents 
and wells at 4 ºC while not in use. 
 Bring ELISA 10X Washing Buffer (12 ml) to room temperature and dilute it to 1X by 
adding 108 ml of deionized water. Mix the buffer by inverting the solution several times. 
 Dilute 60X PEG-HRP to 1X with 1X Antigen/Antibody Diluent Buffer. The volume 
needed will depend on the amount of samples. 
 Mix 27 µl of 1X PEG-HRP with 27 µl of PEGylated samples (standards, unknown 
samples). It is important to make more volume than will be needed. 
 Add 50 µl of the mixture to each well and incubate for 45 minutes at room temperature on 
a shaker. 
 Aspirate each well and wash 3 times with 250 µl 1X washing buffer. 
 Mix TMB A and TMB B (1:1). Add 100 µl of combined substrate solution to each well. 
 Cover to protect from light and incubate for 15 minutes at room temperature without any 
shaking. 
 Add 100 µl of stop solution to each well and make sure that it is mixing properly. 
 Transfer the solution from each well to a V-bottomed 96-well plate (Nunc TM, Thermo 
Scientific). 
 Determine the absorbance at 450 nm using a microplate reader (SoftMax® Pro 
Microplate Reader and Analysis Software). 
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 Appendix III 
Element ratios and volume mean diameters 
 
A) Element Ratios of IXGp-Gd particles in different biological matrices 
Matrix Volume (ml) Si (µM) Gd (µM) 
Ratio 
Si/Gd 
Average 
Si/Gd 
Std. 
Deviation  *SEM 
SBF 0.50 208455.80 9195.60 22.67 - - - 
HS    0.50 225172.20 11056.80   20.37 
21.67 1.14  0.66 HS    0.50  69744.35 3106.91   22.45 
HS    0.50  68522.48 3085.47   22.21 
Urine 0.63 64874.73 2987.31    21.72 - - - 
     *Standard error of the mean 
 
 
B) Element ratios of IXGp-Gd in water 
Sample 
 
Volume 
(ml) Si (µM) P (µM) Gd (µM) 
Ratio 
Si/Gd 
Ratio 
Si/P 
Ratio 
P/Gd 
GF0103 0.1R 0.5 134522.64 105796.80 6134.28 21.93 1.27 17.25 
GF01058 0.1R 0.5 131680.93 98235.90 6031.47 21.83 1.34 16.29 
GF01102 0.1R 0.5 128095.80 92844.00 5461.10 23.46 1.38 17.00 
Average - - - - 22.41 1.33 16.85 
Std.Deviation - - - - 0.91 0.05 0.50 
SEM - - - - 0.53 0.03 0.29 
 
 
C) Volume mean diameter (nm) in different matrices 
Matrix Average size (nm) 
Std 
deviation Range 
Water 4.9 0.4 2.7-6.5 
SBF 5.1 0.3 3.1-6.5 
Urine 6.2 0.90 3.1-10.1 
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D) Volume mean diameter (nm) of IXGp-Gd in SBF o water at room temperature 
Matrix SBF SBF SBF Water Water Water 
Day Mean diam Std.Deviation SEM Mean diam Std.deviation SEM 
0 5.1 0.2 0.06 5.2 0.5 0.14 
1 5.6 0.3 0.08 5.7 0.2 0.07 
2 5.1 0.5 0.15 5.7 0.4 0.12 
3 5.1 0.6 0.19 5.2 1.0 0.33 
4 5.3 0.3 0.10 5.3 0.5 0.16 
5 5.3 0.4 0.14 5.2 0.6 0.19 
8 5.3 0.4 0.11 5.6 0.7 0.23 
16 5.1 0.5 0.16 5.7 0.6 0.19 
 
 
 
E) Volume mean diameter (nm) of IXGp-Gd in SBF at different storage temperatures 
T ºC Room t Room t Room t -20  -20  -20  4  4 4 
Day Mean diam 
Std 
deviation SEM 
Mean 
diam 
Std 
deviation SEM 
Mean 
diam 
Std 
deviation SEM 
0 5.1 0.2 0.06 5.1 0.2 0.06 5.1 0.2 0.06 
1 5.1 0.2 0.05 4.9 0.3 0.09 5.0 0.5 0.15 
2 5.1 0.3 0.10 5.3 0.3 0.08 5.0 0.3 0.08 
3 4.9 0.4 0.11 5.1 0.3 0.10 5.1 0.2 0.05 
4 5.1 0.3 0.08 5.3 0.4 0.12 5.2 0.4 0.11 
5 5.0 0.3 0.09 5.1 0.3 0.10 5.4 0.5 0.16 
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 Appendix IV 
GPC-HPLC chromatograms of nanoparticles 
 
A) IXGp-Gd water nanoparticles (batch 1) 
 
Figure 1. Chromatogram from GPC-HPLC analysis showing the UV (grey) and ELSD (blue) signals from proteins and  
NPs in water respectively. A: albumin; M: myoglobin; NPs: nanoparticles: S: salts. Nanoparticle´s peak was coming out 
1.2 minutes after the albumin peak. 
 
 
B) IXGp-Gd nanoparticles in SBF 
 
Figure 2. Chromatogram from GPC-HPLC analysis showing the UV (green) and ELSD (red) signals from proteins and  
NPs in SBF respectively. A: albumin; M: myoglobin; NPs: nanoparticles: S: salts. Nanoparticle´s peak was coming out 
0.8 minutes after the albumin peak. 
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C)  IXGp-Gd nanoparticles in HS 
 
 
Figure 3. Chromatogram from GPC-HPLC analysis showing the UV (green) and ELSD (red) signals from proteins 
and  NPs in HS respectively. A: albumin; M: myoglobin; NPs: nanoparticles: S: salts. The presence of  proteins in 
high concentrations masks the nanoparticle signal. 
 
 
 
 
 
D) IXGp-Gd nanoparticles in HS (diluted 1:10)  
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Figure 4. Chromatogram from GPC-HPLC analysis showing the UV (green) and ELSD (red) signals 
fromproteins and  NPs in HS 1:10 respectively. A: albumin; M: myoglobin; NPs: nanoparticles: S: salts.; C: 
coating. Nanoparticle´s peak was coming out 0.63 minutes after the albumin peak. 
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 E) XGp-Gd nanoparticles in HS (diluted 1:100) 
 
Figure 5. Chromatogram from GPC-HPLC analysis showing the UV (grey) and ELSD (blue) signals from proteins and 
NPs in HS 1:100 respectively. A: albumin; M: myoglobin; NPs: nanoparticles: S: salts; C: coating. Nanoparticle´s peak 
was coming out 0.51 minutes after the albumin peak. 
F) IXGp-Gd nanoparticles in water (batch 2)  
 
Figure 6. Chromatogram from GPC-HPLC analysis showing the UV (grey) and ELSD (blue) signals from proteins and 
NPs in water respectively. A: albumin; M: myoglobin; NPs: nanoparticles: S: salts; C: coating. Nanoparticle´s peak was 
coming out 1.0 minutes after the albumin peak. 
 
G) IXGp-Gd nanoparticles in urine 
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Figure 7. Chromatogram from GPC-HPLC analysis showing the UV (green) and ELSD (red) signals from proteins and 
NPs in urine respectively. A: A:albumin; M: myoglobin; NPs: nanoparticles: S: salts; C: coating. Nanoparticle´s peak w  
coming out 0.4 minutes after the albumin peak. 
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 Appendix V 
ELISA Standard curves in different biological matrices 
Water Batch 1 
    
Sample [Si]uM Abs 450 nm Expected [PEG]uM Measured [PEG]uM Standard deviation 
Std 1 0.55 0.34 0.13 0.01 -0.92 
Std 2 1.09 0.16 0.26 0.34 0.29 
Std 3 2.19 0.09 0.53 0.60 0.14 
Std 4 4.37 0.03 1.06 1.09 0.03 
Std 5 8.75 0.00 2.12 1.91 -0.10 
Water Batch 2 
    Sample [Si]uM Abs 450 nm Expected [PEG]uM Measured [PEG]uM Standard deviation 
Std 1 0.20 1.09 0.05 0.01 -0.75 
Std 2 0.66 0.71 0.16 0.14 -0.11 
Std 3 1.25 0.37 0.30 0.35 0.14 
Std 4 2.50 0.13 0.60 0.66 0.09 
Std 5 4.00 0.06 0.97 0.93 -0.04 
SBF 
     
Sample [Si]uM Abs 450 nm Expected [PEG]uM Measured [PEG]uM Standard deviation 
Std 1 0.20 0.59 0.05 -0.23 -5.70 
Std 2 0.66 0.26 0.16 0.13 -0.20 
Std 3 1.25 0.15 0.30 0.35 0.16 
Std 4 2.50 0.06 0.60 0.74 0.23 
Std 5 4.00 0.03 0.97 1.01 0.04 
 
     HS 
     
Sample [Si]uM Abs 450 nm Expected [PEG]uM Measured [PEG]uM Standard deviation 
Std 1 0.20 0.43 0.05 -0.09 -2.85 
Std 2 0.66 0.18 0.16 0.27 0.70 
Std 3 1.25 0.17 0.30 0.31 0.04 
Std 4 2.50 0.08 0.60 0.63 0.04 
Std 5 4.00 0.02 0.97 1.18 0.22 
  
    Urine 
     
Sample [Si]uM Abs 450 nm Expected [PEG]uM Measured [PEG]uM  Standard deviation 
Std 1 0.20 0.81 0.05 0.05 -0.07 
Std 2 0.66 0.28 0.16 0.21 0.30 
Std 3 1.25 0.25 0.30 0.24 -0.21 
Std 4 2.50 0.13 0.60 0.64 0.05 
Std 5 4.00 0.09 0.97 0.97 0.00 
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 Appendix VI 
ICP-OES accuracy: concentration determination of Si, P and Gd 
Correction factor = Expected / Measured (ICP-OES) 
 
Gd      
Sample Expected Gd (µM) Matrix 
ICP matrix 
(% HNO3) 
Gd 
measured 
(µM) 
Correction 
factor 
1 298,96 Water 1%  285,73 1,05 
2 99,65 Water 1%  106,21 0,94 
3 9,97 Water 1%  9,50 1,05 
4 1,00 Water 1%  0,56 1,77 
5 298,96 HS 1%  321,35 0,93 
6 99,65 HS 1%  109,37 0,91 
7 9,97 HS 1%  10,12 0,98 
8 1,00 HS 1%  0,64 1,55 
9 298,96 HS 0.1%  224,39 1,33 
10 99,65 HS 0.1%  69,29 1,44 
11 9,97 HS 0.1%  7,55 1,32 
12 1,00 HS 0.1% 0,58 1,73 
13 298,96 Urine 1% 309,21 0,97 
14 99,65 Urine 1%  108,67 0,92 
15 9,97 Urine 1% 9,86 1,01 
16 1,00 Urine 1% 0,62 1,61 
17 298,96 SBF 1%  307,62 0,97 
18 99,65 SBF 1%  109,21 0,91 
19 9,97 SBF 1%  9,94 1,00 
20 1,00 SBF 1%  0,57 1,74 
21 Reference Water 1% 6297,92 - 
22 Reference Water 1% 6280,83 - 
23 Reference Water 1% 6255,50 - 
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 Si      
Sample Expected Si  (µM) Matrix 
ICP 
matrix  
(% HNO3) 
Si 
measured 
(uM) 
Correction 
factor 
1 5539,35 Water 1%  5847,70 0,95 
2 1846,45 Water 1%  1952,33 0,95 
3 184,64 Water 1%  202,34 0,91 
4 18,46 Water 1%  16,95 1,09 
5 5539,35 HS 1%  6678,92 0,83 
6 1846,45 HS 1%  2274,18 0,81 
7 184,64 HS 1%  229,26 0,81 
8 18,46 HS 1%  18,70 0,99 
9 5539,35 HS 0.1%  5136,40 1,08 
10 1846,45 HS 0.1%  1681,56 1,10 
11 184,64 HS 0.1%  171,07 1,08 
12 18,46 HS 0.1%  13,44 1,37 
13 5539,35 Urine 1%  5605,73 0,99 
14 1846,45 Urine 1%  1899,83 0,97 
15 184,64 Urine 1%  192,67 0,96 
16 18,46 Urine 1%  18,53 1,00 
17 5539,35 SBF 1%  5617,08 0,99 
18 1846,45 SBF 1%  1921,96 0,96 
19 184,64 SBF 1%  195,61 0,94 
20 18,46 SBF 1%  16,88 1,09 
21 Reference Water 1%  116003,49 - 
22 Reference Water 1%  118251,50 - 
23 Reference Water 1%  114739,48 - 
 
 
P      
Sample Expected P (µM) Matrix 
ICP matrix 
(% HNO3) 
p 
measured 
(uM) 
Correction 
factor 
1 4240,37 Water 1%  4674,47 0,91 
2 1413,46 Water 1%  1549,92 0,91 
3 141,35 Water 1%  160,50 0,88 
4 14,13 Water 1%  12,92 1,09 
5 Reference Water 1%  88728,94 - 
6 Reference Water 1%  90407,93 - 
7 Reference Water 1%  88018,39 - 
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 Appendix VII 
GPC-HPLC chromatograms of fractionated nanoparticles  
 
A) Fractions 2-6 in water 
 
B) Fractions 2-6 in SBF  
 
C) Fractions 1-6 in HS  
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 D) Fractions 2-6 in HS (1:10) 
 
 
E) Fraction 2-6 in HS (1:100)  
 
 
 
F) Fractions 2-6 in urine 
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 Appendix VIII 
Protein and nanoparticle concentrations (µg/ml) in serum and urine fractions 
 
A) Fractions in HS 
Sample [NPs] (µg /ml) 
[Protein] 
(µg/ml)* 
Ratio 
protein/NP 
GF01058 0.1R 28494,26 50520,38 1,77 
F1 17,00 192,22 11,31 
F2 176,62 512,85 2,90 
F3 482,90 1996,80 4,13 
F4 353,53 592,43 1,68 
F5 30,86 9,96 0,32 
F6 3,48 2,26 0,65 
F7 0,82 0,00 0,00 
∑ 1065,21 3306,52 - 
*Obtained with Bradford assay (see 3.9.2 Material and Methods) 
 
 
B) Fractions in HS 1:10 
Sample [NPs] (µg /ml) 
[Protein] 
(µg/ml) * 
Ratio 
protein/NP 
GF01058 0.1R 8825,75 4726,53 0,54 
F1 0,84 1,46 1,74 
F2 146,55 83,90 0,57 
F3 269,83 50,75 0,19 
F4 119,64 6,45 0,05 
F5 17,59 0,70 0,04 
F6 2,43 1,46 0,60 
F7 0,14 0,70 5,06 
∑ 557,01 145,43 - 
                              *Obtained with Bradford assay (see 3.9.2 Material and Methods) 
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 C) Fractions in HS 1:100 
Sample [NPs] 
(µg /ml) 
[Protein] 
(µg/ml)* 
Ratio 
protein/NP 
GF01058 0.1R 8671,13 672,71 0,08 
F1 0,28 1,46 5,31 
F2 109,94 3,90 0,04 
F3 256,92 7,32 0,03 
F4 113,83 3,90 0,03 
F5 18,63 0,70 0,04 
F6 2,46 3,07 1,25 
F7 0,06 1,46 23,38 
∑ 502,11 21,83 - 
                                    * Obtained with Bradford assay (see 3.9.2 Material and Methods) 
 
 
D) Fractions in urine 
Sample [NPs] 
(µg /ml) 
[Protein] 
(µg/ml) * 
Ratio 
protein/NP 
GF01058 0.1R 8209,53 18,12 0,00 
F1 0,93 4,74 5,10 
F2 137,25 3,07 0,02 
F3 217,11 3,90 0,02 
F4 107,16 3,07 0,03 
F5 15,81 1,46 0,09 
F6 2,03 0,70 0,34 
F7 0,40 3,07 7,59 
∑ 480,70 20,03 - 
                                   * Obtained with Bradford assay (see 3.9.2 Material and Methods) 
 
Appendix IX 
Fractionation dates in the different matrices 
Matrix Date Matrix Date Matrix Date 
Water 1º 2015-03-10 HS 2015-03-04 Urine 2015-03-17 
Water 2º 2015-03-28 HS 1:10 2015-03-20 - - 
SBF 2015-03-02 HS 1:100 2015-03-23 - - 
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 POPULAR SCIENCE SUMMARY 
Gema Fernández 
Tracing nanoparticles in biological matrices 
Cancer includes a heterogeneous group of diseases that arises due to an uncontrolled 
proliferation of cells which are able to invade normal tissues. Magnetic resonance imaging 
(MRI) has been widely used to detect cancer in its earliest stage. However, there is a need 
for new contrast agents (CAs) with higher sensitivity. Consequently, cancer nanotechnology 
has emerged as a new potential field which includes the design of material in a scale range 
from 1-100 nanometers with clinical use for cancer therapy and diagnosis.  
Nanomaterials include a wide range of particles used as versatile molecular devices like vectors 
for drug delivery or CAs to enhance contrast images from tumor tissues. Spago Nanomedical AB 
in Lund is studying a potential nanomaterial-based contrast agent to be used in MRI. The main 
structure of the nanoparticle consists of a polymeric central core, which contains a metal ion 
inside, together with a coating attached to the surface (Figure 1). This coating is made of 
polyethylene glycol (PEG) chains which form a passive surface that reduces aggregation and 
undesired interactions in the body.  
 
 
 
 
Do nanoparticles look the same after being injected into the body? 
In this project, a dummy particle mimicking a nanoparticle-based contrast agent was further 
investigated to set up a combined bioanalysis method to extract and characterize the nanomaterial 
from relevant biological matrices (e.g urine, serum). The final goal was to demonstrate that the 
identity of the particles (the main physicochemical properties) remain unaffected after being 
injected into the blood of animals during in vivo trials. Problems can arise if the content of the 
nanoparticles is released to the biological fluids or if particles aggregate and lodge somewhere in 
the body. The nanoparticles were isolated and separated by size using gel permeation 
chromatography (GPC). The resulting fractions were analyzed in terms of composition and 
coating using inductively coupled plasma optical emission spectroscopy (ICP-OES) and enzyme-
linked immunosorbent assay (ELISA) respectively. The results proved the presence of 
nanomaterial in the biological matrices and showed a successful separation of the nanoparticles 
by size with high rate of recovery. Furthermore, it was possible to analyze the core and coating 
components of the extracted material in an accurate and efficient way. This study shows the 
importance of characterizing the nanomaterial and proves its identity before going into clinical 
trials. 
These particles can be delivered into the tumor 
tissue through passive targeting. This strategy 
can be used because during their growth, 
cancer cells create new but defective blood 
vessels. Thus, tumor vasculature has an 
enhanced permeability and lack of an efficient 
lymphatic drainage which gives rise to the so 
called enhanced permeability and retention 
(EPR) effect. This effect allows the 
nanoparticles to accumulate selectively in the 
tumor and remain there for a longer time 
compared to a normal tissue.  
 
 
 
Figure 1. Nanoparticle structure consisting of a central core with a 
metal ion inside and a coating attached to the surface of the 
particle. NP: nanoparticle; PEG: polyethylene glycol; Gd: 
gadolinium. 
Advisor: Dr. Sania Bäckström  
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